Blueprint

0001654954-16-001315.txt : 20160809 0001654954-16-001315.hdr.sgml : 20160809 20160809163146 ACCESSION NUMBER: 0001654954-16-001315 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20160630 FILED AS OF DATE: 20160809 DATE AS OF CHANGE: 20160809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11889 FILM NUMBER: 161818402 BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 10-Q 1 cvm_10q.htm QUARTERLY REPORT Blueprint

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2016

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to ______________.

Commission File Number 001-11889

CEL-SCI CORPORATION

Colorado		84-0916344
State or other jurisdiction incorporation		(IRS) Employer Identification Number

8229 Boone Boulevard, Suite 802

Vienna, Virginia 22182

Address of principal executive offices

(703) 506-9460

Registrant's telephone number, including area code

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) had been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check One):

Large accelerated filer ☐ Accelerated filer ☒

Non-accelerated filer ☐ Smaller reporting company ☐

(Do not check if a smaller reporting company)

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

Class of Stock	No. Shares Outstanding	Date
Common	145,349,718	August 1, 2016

TABLE OF CONTENTS

	Page
PART I FINANCIAL INFORMATION

Item 1.

Condensed Balance Sheets at June 30, 2016 and September 30, 2015 (unaudited)	2

Condensed Statements of Operations for the nine months Ended June 30, 2016 and 2015 (unaudited)	3

Condensed Statements of Operations for the three months Ended June 30, 2016 and 2015 (unaudited)	4

Condensed Statements of Cash Flows for the nine months Ended June 30, 2016 and 2015 (unaudited)	5

Notes to Condensed Financial Statements (unaudited)	7

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	22

Item 3. Quantitative and Qualitative Disclosures about Market Risks	26

Item 4. Controls and Procedures	26

PART II

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	28

Item 6. Exhibits	28

Signatures	29

CEL-SCI CORPORATION
BALANCE SHEETS
(UNAUDITED)

	JUNE 30,	SEPTEMBER 30,
ASSETS	2016	2015

CURRENT ASSETS:
Cash and cash equivalents	$5,218,960	$5,726,682
Receivables	790,658	87,214
Prepaid expenses	713,549	979,655
Deposits - current portion	150,000	150,000
Inventory used for R&D and manufacturing	1,259,458	1,401,839
Deferred rent - current portion	444,349	487,793

Total current assets	8,576,974	8,833,183

RESEARCH AND OFFICE EQUIPMENT, net	250,552	307,466

PATENT COSTS, net	266,493	291,564

DEFERRED RENT - net of current portion	3,565,684	4,044,473

DEPOSITS	1,820,917	1,970,917

TOTAL ASSETS	$14,480,620	$15,447,603



LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES:
Accounts payable	$4,437,389	$5,128,682
Accrued expenses	520,973	88,575
Due to employees	316,804	365,131
Related party loan	-	1,104,057
Deferred rent - current portion	4,037	9,997
Lease obligation - current portion	2,309	9,028

Total current liabilities	5,281,512	6,705,470

Derivative instruments	12,823,052	13,686,587
Deferred revenue	126,501	126,639
Deferred rent - net of current portion	18,378	9,026
Deposits held	5,000	5,000

Total liabilities	18,254,443	20,532,722

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' DEFICIT
Preferred stock, $.01 par value--200,000 shares authorized;
-0- shares issued and outstanding	-	-
Common stock, $.01 par value - 600,000,000 shares authorized,
145,146,097 shares and 112,360,568 shares issued and outstanding
at June 30, 2016 and September 30, 2015, respectively	1,451,461	1,123,606
Additional paid-in capital	279,328,561	267,992,754
Accumulated deficit	(284,553,845)	(274,201,479)

Total stockholders' deficit	(3,773,823)	(5,085,119)

TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT	$14,480,620	$15,447,603

See notes to financial statements.

CEL-SCI CORPORATION
STATEMENTS OF OPERATIONS
NINE MONTHS ENDED JUNE 30, 2016 and 2015
(UNAUDITED)

	2016	2015

GRANT INCOME AND OTHER	$183,726	$723,681

OPERATING EXPENSES:
Research and development	14,636,197	15,701,986
General & administrative	3,987,011	10,978,254

Total operating expenses	18,623,208	26,680,240

OPERATING LOSS	(18,439,482)	(25,956,559)

GAIN ON DERIVATIVE INSTRUMENTS	8,037,974	1,808,954

LOSS ON DEBT EXTINGUISHMENT	-	(641,276)

INTEREST INCOME (EXPENSE), NET	49,142	(41,810)

NET LOSS	$(10,352,366)	$(24,830,691)

NET LOSS PER COMMON SHARE
BASIC AND DILUTED	$(0.09)	$(0.32)

WEIGHTED AVERAGE COMMON SHARES
OUTSTANDING
BASIC AND DILUTED	117,412,443	77,625,511

See notes to financial statements.

CEL-SCI CORPORATION
STATEMENTS OF OPERATIONS
THREE MONTHS ENDED JUNE 30, 2016 and 2015
(UNAUDITED)

	2016	2015

GRANT AND OTHER INCOME	$129,975	$389,223

OPERATING EXPENSES:
Research and development	4,838,108	5,727,577
General & administrative	1,674,614	2,863,121

Total operating expenses	6,512,722	8,590,698

OPERATING LOSS	(6,382,747)	(8,201,475)

GAIN ON DERIVATIVE INSTRUMENTS	2,508,744	4,428,780

LOSS ON DEBT EXTINGUISHMENT	-	(641,276)

INTEREST INCOME (EXPENSE), NET	24,679	(15,166)

NET LOSS	$(3,849,324)	$(4,429,137)

NET LOSS PER COMMON SHARE
BASIC	$(0.03)	$(0.05)

DILUTED	$(0.03)	$(0.06)

WEIGHTED AVERAGE COMMON SHARES
OUTSTANDING
BASIC	124,132,500	83,796,311

DILUTED	124,132,500	85,134,107

See notes to financial statements.

CEL-SCI CORPORATION
STATEMENTS OF CASH FLOWS
NINE MONTHS ENDED JUNE 30, 2016 and 2015
(UNAUDITED)

	2016	2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$(10,352,366)	$(24,830,691)
Adjustments to reconcile net loss to
net cash used in operating activities:
Depreciation and amortization	118,272	163,431
Issuance of common stock and options for services	618,890	437,729
Equity based compensation	1,263,662	4,570,999
Common stock contributed to 401(k) plan	120,693	123,066
Loss on retired equipment	115	313
Gain on derivative instruments	(8,037,974)	(1,808,954)
Loss on debt extinguishment	-	641,276
(Increase)/decrease in assets:
Receivables	5,854	(76,672)
Deferred rent	522,233	559,828
Prepaid expenses	267,742	(283,864)
Inventory used for R&D and manufacturing	142,381	36,513
Deposits	150,000	150,000
Increase/(decrease) in liabilities:
Accounts payable	(1,079,423)	1,856,635
Accrued expenses	86,398	(117,207)
Due to employees	(48,327)	95,214
Deferred rent liability	3,392	(5,795)
Deferred revenue	(138)	(1,591)

Net cash used in operating activities	(16,218,596)	(18,489,770)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment	(31,405)	(56,616)
Expenditure for patent costs	(5,008)	(9,422)
Net cash used in investing activities	(36,413)	(66,038)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants	16,858,029	21,278,905
Payment on related party loan	(1,104,057)	-
Payments on obligations under capital lease	(6,685)	(6,290)

Net cash provided by financing activities	15,747,287	21,272,615

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(507,722)	2,716,807

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	5,726,682	8,513,620

CASH AND CASH EQUIVALENTS, END OF PERIOD	$5,218,960	$11,230,427

See notes to financial statements.

CEL-SCI CORPORATION
STATEMENTS OF CASH FLOWS
NINE MONTHS ENDED JUNE 30, 2016 and 2015
(UNAUDITED)

SUPPLEMENTAL DISCLOSURE OF NON-CASH CHANGES
	2016	2015


ACCOUNTS PAYABLE
Increase in receivables	$363,298	$-
Increase in research and office equipment	-	12,625
(Decrease) in patent costs	(12)	(975)
Decrease in capital lease obligation	34	32
Increase in direct financing costs	24,810	128,630
(Increase) in accounts payable	(388,130)	(140,312)
	$-	$-


ACCRUED EXPENSES
Increase in receivables	$346,000	$-
(Increase) in accrued expenses	(346,000)	-
	$-	$-


ADDITIONAL PAID-IN CAPITAL
(Increase) in derivative liabilities	$(7,174,439)	$(8,463,957)
Decrease in common stock	-	1,000
Increase in prepaid services	1,636	20,464
Decrease in additional paid-in capital	7,172,803	8,442,493
	$-	$-


SUPPLEMENTAL DISCLOSURE OF CASH FLOWS
INFORMATION:
Cash paid for interest expense	$43,646	$124,914

See notes to financial statements.

CEL-SCI CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

NINE MONTHS ENDED JUNE 30, 2016 AND 2015 (UNAUDITED)

A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s annual report on Form 10-K for the year ended September 30, 2015.

In the opinion of management, the accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the Company’s financial position as of June 30, 2016 and the results of its operations for the nine and three months then ended. The condensed balance sheet as of September 30, 2015 is derived from the September 30, 2015 audited financial statements. Significant accounting policies have been consistently applied in the interim financial statements and the annual financial statements. The results of operations for the nine and three months ended June 30, 2016 are not necessarily indicative of the results to be expected for the entire year.

Summary of Significant Accounting Policies:

Research and Office Equipment and Leasehold Improvements - Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Research and office equipment are reviewed on a quarterly basis to determine if any of the assets are impaired.

Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made in the period identified. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Research and Development Costs - Research and development costs are expensed as incurred.

Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2016 and September 30, 2015.

Derivative Instruments – The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are remeasured at fair value at the end of each reporting period as long as they are outstanding.

Deferred Rent (Asset) – Consideration paid, including deposits, related to operating leases is recorded as a deferred rent asset and amortized as rent expense over the lease term. Interest on deferred rent is calculated at 3% on the funds deposited on the manufacturing facility and is included in deferred rent. This interest income will be used to offset future rent.

Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation – Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period.

Equity instruments issued to non-employees are accounted for in accordance with ASC 505-50, “Equity-Based Payments to Non Employees.” Accordingly, compensation is recognized when goods or services are received and options issued are measured using the Black-Scholes valuation model. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected life of the options.

The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders.

The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s common stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with term equal to the expected life of the option. Historical data was used to estimate option exercise and employee termination within the valuation model. The expected term of options represents the period of time that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.

Vesting of restricted stock granted under the Incentive Stock Bonus Plan is subject to service, performance and market conditions and meets the classification of equity awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.

Reclassification – Certain prior year items have been reclassified to conform to the current year presentation. Such reclassifications include approximately $145,000 between related party notes payable and additional paid-in capital to reflect the modification of the note payable to the de Clara Trust in July 2015, which was accounted for as an extinguishment.

B. NEW ACCOUNTING PRONOUNCEMENTS

In January 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new guidance is intended to improve the recognition and measurement of financial instruments. The new guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted for specific provisions within the guidance. Management does not expect the new standard to have a material effect on its financial statements and related disclosures.

In February 2016, the FASB issued ASU 2016-02, Leases, which will require most leases (with the exception of leases with terms of less than one year) to be recognized on the balance sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning with the earliest comparative period presented. The Company is currently evaluating the effect of the new standard on its financial statements and related disclosures.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 simplifies several aspects of the accounting for share-based payment award transactions, including income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2016 but early adoption is permitted. The Company is currently evaluating the effect of the new amendment on its financial statements and related disclosures.

The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

C. STOCKHOLDERS’ EQUITY

Stock options, stock bonuses and compensation granted by the Company as of June 30, 2016 are as follows:

Name of Plan	Total Shares Reserved Under Plans	Shares Reserved for Outstanding Options	Shares Issued	Remaining Options/Shares Under Plans

Incentive Stock Options Plans	1,960,000	1,685,966	N/A	11,334
Non-Qualified Stock Option Plans	7,680,000	6,005,721	N/A	1,062,861
Stock Bonus Plans	3,594,000	N/A	2,562,950	1,030,223
Stock Compensation Plan	3,350,000	N/A	1,767,047	1,549,905
Incentive Stock Bonus Plan	16,000,000	N/A	15,600,000	400,000

Stock options, stock bonuses and compensation granted by the Company as of September 30, 2015 are as follows:

Name of Plan	Total Shares Reserved Under Plans	Shares Reserved for Outstanding Options	Shares Issued	Remaining Options/Shares Under Plans

Incentive Stock Option Plans	1,960,000	1,690,665	N/A	6,635
Non-Qualified Stock Option Plans	7,680,000	5,849,103	N/A	1,219,479
Bonus Plans	3,594,000	N/A	1,643,714	1,949,459
Stock Compensation Plan	3,350,000	N/A	1,423,999	1,892,950
Incentive Stock Bonus Plan	16,000,000	N/A	15,600,000	400,000

Stock option activity:

	Nine Months Ended June 30,
	2016	2015
Granted	210,000	803,700
Forfeited	55,998	137,249

	Three Months Ended June 30,
	2016	2015
Granted	0	801,700
Forfeited	5,000	27,833

No shares of restricted stock were forfeited from the Incentive Stock Bonus Plan during the nine and three months ended June 30, 2016. During the nine and three months ended June 30, 2015, 100,000 and 0 shares, respectively, of non-vested restricted stock were forfeited.

Stock-Based Compensation Expense

	Nine Months Ended June 30,
	2016	2015
Employees	$1,263,662	$4,570,999
Non-employees	$618,890	$437,729

	Three months Ended June 30,
	2016	2015
Employees	$418,562	$619,145
Non-employees	$146,830	$137,600

Employee compensation expense includes the expense related to options issued or vested and restricted stock. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of their service contracts.

Derivative Liabilities, Warrants and Other Options

The following chart presents the derivative liabilities, warrants and other options outstanding during the quarter ended June 30, 2016:

Warrant	Issue Date	Shares Issuable upon Exercise of Warrant	Exercise Price	Expiration Date	Refer-ence

Series R	12/6/12	2,625,000	$4.00	12/6/16	1
Series S	10/11/13 -10/24/14	25,928,010	$1.25	10/11/18	1
Series U	4/17/14	445,514	$1.75	10/17/17	1
Series V	5/28/15	20,253,164	$0.79	5/28/20	1
Series W	10/28/15	17,223,248	$0.67	10/28/20	1
Series Z	5/23/16	6,600,000	$0.55	11/23/21	1
Series ZZ	5/23/16	500,000	$0.55	5/18/21	1
Series X	1/13/16	3,000,000	$0.37	1/13/21	2
Series Y	2/15/16	650,000	$0.48	2/15/21	2
Series N	8/18/08	2,844,627	$0.53	8/18/17
Series P	2/10/12	590,001	$4.50	3/6/17
Consultants	12/2/11- 1/1/16	440,000	$0.37- $3.50	10/27/16- 12/31/18	3

The following chart presents the derivative liabilities, warrants and other options outstanding at September 30, 2015:

Warrant	Issue Date	Shares Issuable upon Exercise of Warrants	Exercise Price	Expiration Date	Refer-ence

Series N	8/18/08	2,844,627	0.53	8/18/17
Series Q	6/21/12	1,200,000	5.00	12/22/15	1
Series R	12/6/12	2,625,000	4.00	12/6/16	1
Series S	10/11/13- 10/24/14	25,928,010	1.25	10/11/18	1
Series U	4/17/14	445,514	1.75	10/17/17	1
Series V	5/28/15	20,253,164	0.79	5/28/20	1
Series P	2/10/12	590,001	4.50	3/6/17
Consultants	10/14/05 – 7/1/15	238,000	0.66 – 20.00	10/14/15 - 6/30/18	3

Derivative Liabilities

The table below presents the derivative instruments and their respective balances at the balance sheet dates:

	June 30, 2016	September 30, 2015
Series S warrants	$3,930,686	$7,363,555
Series U warrants	4,455	44,551
Series V warrants	3,443,038	6,278,481
Series W warrants	3,557,971	-
Series Z warrants	1,756,982	-
Series ZZ warrants	129,920	-

Total derivative liabilities	$12,823,052	$13,686,587

The gains on the derivative instruments are as follows:

	Nine Months Ended June 30,
	2016	2015
Series A through E warrants	$-	$6,105
Series H warrants	-	12,000
Series Q warrants	-	12,000
Series R warrants	-	131,250
Series S warrants	3,432,869	472,487
Series U warrants	40,096	74,352
Series V warrants	2,835,443	1,100,760
Series W warrants	1,502,800	-
Series Z warrants	210,848	-
Series ZZ warrants	15,918	-

Gain on derivative instruments	$8,037,974	$1,808,954

	Three Months Ended June 30,
	2016	2015
Series H warrants	$-	$12,000
Series Q warrants	-	12,000
Series R warrants	-	105,000
Series S warrants	285,208	3,111,361
Series U warrants	13,366	87,659
Series V warrants	1,012,658	1,100,760
Series W warrants	970,746
Series Z warrants	210,848	-
Series ZZ warrants	15,918	-

Gain on derivative instruments	$2,508,744	$4,428,780

The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company’s stock because future equity offerings or sales of the Company’s stock are not an input to the fair value of a “fixed-for-fixed” option on equity shares, and equity classification is therefore precluded.

In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting dates is recognized as a gain or loss.

Issuance of additional Warrants

On May 23, 2016, the Company closed a registered direct offering of 10,000,000 shares of common stock and 6,600,000 Series Z warrants to purchase shares of common stock. The common stock and warrants were sold at a combined per unit price of $0.50 for net proceeds of approximately $4.6 million, net of placement agent’s commissions and offering expenses. The Series Z warrants may be exercised at any time on or after November 23, 2016 and on or before November 23, 2021 at a price of $0.55 per share. The Company also issued 500,000 Series ZZ warrants to the placement agent as part of its compensation. The Series ZZ warrants may be exercised at any time on or after November 23, 2016 and on or before May 18, 2021 at a price of $0.55 per share. The fair value of the Series Z and Series ZZ warrants of $2.1 million on the date of issuance was recorded as a warrant liability.

On October 28, 2015, the Company closed an underwritten public offering of 17,223,248 shares of common stock and 17,223,248 Series W warrants to purchase shares of common stock. The common stock and warrants were sold at a combined per unit price of $0.67 for net proceeds of approximately $10.5 million, net of underwriting discounts and commissions and offering expenses. The Series W warrants are immediately exercisable at a price of $0.67 and expire on October 28, 2020. The fair value of the Series W warrants of $5.1 million on the date of issuance was recorded as warrant liability.

Expiration of Warrants

On December 22, 2015, 1,200,000 Series Q warrants, with an exercise price of $5.00, expired. The fair value of the Series Q warrants was $0 on the date of expiration.

Equity-based warrants

In January 2016, the Company sold 3,000,000 shares of its common stock and 3,000,000 Series X warrants to the de Clara Trust for approximately $1.1 million. The de Clara Trust is controlled by Geert Kersten, the Company's Chief Executive Officer and a director. Each Series X warrant allows the de Clara Trust to purchase one share of the Company's common stock at a price of $0.37 per share at any time on or before January 13, 2021. The Series X warrants qualify for equity treatment in accordance with ASC 815. The relative fair value of the warrants was calculated to be approximately $417,000.

In February 2016, the Company sold 1,300,000 shares of its common stock and 650,000 Series Y warrants to a private investor for $624,000. Each Series Y warrant allows the holder to purchase one share of the Company's common stock at a price of $0.48 per share at any time on or before February 15, 2021. The Series Y warrants qualify for equity treatment in accordance with ASC 815. The relative fair value on the date of issuance of the warrants was calculated to be approximately $144,000.

Options and shares issued to consultants

The Company typically enters into consulting arrangements in exchange for common stock or stock options. During the nine and three months ended June 30, 2016, the Company issued 990,045 and 186,267 shares of common stock, respectively, of which 647,000 and 67,000, respectively, were restricted shares. Under these arrangements, the common stock was issued with stock prices ranging between $0.37 and $0.72 per share. During the nine and three months ended June 30, 2015, the Company issued 584,476 and 160,492 shares of common stock, respectively, of which 127,000 and 58,000, respectively, were restricted shares. Under these arrangements, the common stock was issued with stock prices ranging between $0.57 and $1.11 per share.

Additionally, during the nine and three months ended June 30, 2016, the Company issued 210,000 and 0 of fully vested options, respectively, to purchase common stock with a fair value ranging between $0.19 and $0.30 per share. During the nine and three months ended June 30, 2015, the Company issued 40,000 and 0 options, respectively, to purchase common stock with a fair value of $0.50 per share. The aggregate values of the issuances of restricted common stock and common stock options are recorded as prepaid expenses and are charged to general and administrative expenses over the periods of service.

During the nine and three months ended June 30, 2016, the Company recorded total expense of approximately $619,000 and $147,000, respectively, relating to these consulting agreements. During the nine and three months ended June 30, 2015, the Company recorded total expense of approximately $438,000 and $138,000, respectively, relating to these consulting agreements. At June 30, 2016 and September 30, 2015, approximately $32,000 and $30,000, respectively, are included in prepaid expenses. As of June 30, 2016, 440,000 vested options issued to consultants as payment for services remained outstanding, all of which were issued from the Non-Qualified Stock Option plans.

D. FAIR VALUE MEASUREMENTS

In accordance with ASC 820-10, “Fair Value Measurements,” the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.

ASC 820-10 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:

●

Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities

●

Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets

●

Level 3 – Unobservable inputs that reflect management’s assumptions

For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at June 30, 2016:

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total

Derivative instruments	$3,930,686	$-	$8,892,366	$12,823,052

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2015:

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total

Derivative instruments	$7,363,555	$-	$6,323,032	$13,686,587

The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for the nine months ended June 30, 2016 and the year ended September 30, 2015:

	(9 months ended)	(12 months ended)
	June 30, 2016	September 30, 2015
Beginning balance	$6,323,032	$307,894
Issuances	7,174,439	8,003,220
Realized and unrealized gains	(4,605,105)	(1,988,082)
Ending balance	$8,892,366	$6,323,032

The fair values of the Company’s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company’s stock, as well as U.S. Treasury Bill rates, are observable in active markets.

E. RELATED PARTY LOAN

On January 12, 2016, the Company owed the de Clara Trust $1,105,989, which amount included accrued and unpaid interest. On January 13, 2016, the de Clara Trust demanded payment on the note payable. At the same time the Company sold 3,000,000 shares of its common stock and 3,000,000 Series X warrants to the de Clara Trust for approximately $1.1 million. Each warrant allows the de Clara Trust to purchase one share of the Company's common stock at a price of $0.37 per share at any time on or before January 13, 2021.

Prior to the repayment, on June 29, 2015, the Company had extended the maturity date of the note to July 6, 2017, lowered the interest rate from 15% to 9% and changed the conversion price from $4.00 to $0.59, the closing stock price on the previous trading day. The Company determined these modifications to be substantive and accounted for the modification as an extinguishment of the pre-modification note and issuance of the post-modification note. The Company recorded an extinguishment loss and a premium on the note payable of approximately $166,000. The premium was credited to additional paid-in capital.

During the nine and three months ended June 30, 2016, the Company paid approximately $43,000 and $0, respectively, in interest expense to Mr. de Clara. During the nine and three months ended June 30, 2015, the Company paid approximately $124,000 and $41,000, respectively, in interest expense to Mr. de Clara.

F. OPERATIONS AND FINANCING

The Company has incurred significant costs since its inception in connection with the acquisition of certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities, and clinical trials. The Company has funded such costs with proceeds from loans and the public and private sale of its common stock. The Company will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts. To date, the Company has not generated any revenue from product sales. The ability of the Company to complete the necessary clinical trials and obtain US Food & Drug Administration (FDA) approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.

The Company is currently running a large multi-national Phase 3 clinical trial for head and neck cancer with its partners TEVA Pharmaceuticals and Orient Europharma. During the nine months ended June 30, 2016, the Company raised $16.8 million in net proceeds from public and private sales of common stock and warrants. To finance the study for the next twelve months and beyond, the Company plans to raise additional capital in the form of corporate partnerships, as well as debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine is a product in the Phase 3 clinical trial stage. However, the operating plan may change as a result of many factors currently unknown to the Company, and the Company may need additional funds sooner than planned. There can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it will either have to slow the development of the Phase 3 clinical trial or even significantly curtail its operations until such time as it is able to raise the required funding.

Since the Company launched its Phase 3 clinical trial for Multikine, the Company has spent approximately $31.9 million as of June 30, 2016 on direct costs for the Phase 3 clinical trial.

The financial statements have been prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

G. COMMITMENTS AND CONTINGENCIES

Clinical Research Agreements

In March 2013, the Company entered into an agreement with Aptiv Solutions to provide certain clinical research services in accordance with a master service agreement. The Company will reimburse Aptiv for costs incurred. The agreement required the Company to make $600,000 in advanced payments which are being credited back in $150,000 annual increments through December 2017. As of June 30, 2016, the total balance advanced is $300,000, of which $150,000 is classified as a current asset.

In April 2013, the Company entered into a co-development and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million towards the study in the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. In October 2015 the Company entered into a second co-development and revenue sharing agreement with Ergomed for an additional $2 million, for a total of $12 million. The Company accounted for the co-development and revenue sharing agreement in accordance with ASC 808 “Collaborative Arrangements.” The Company determined the payments to Ergomed are within the scope of ASC 730 “Research and Development.” Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the Company entered into the co-development and revenue sharing agreement with Ergomed, it has incurred research and development expenses of approximately $17.8 million related to Ergomed’s services. This amount is net of Ergomed’s discount of approximately $5.9 million. During the nine and three months ended June 30, 2016, the Company recorded, net of Ergomed’s discount, approximately $5.9 million and $2.1 million, respectively, as research and development expense related to Ergomed’s services. During the nine and three months ended June 30, 2015, the Company recorded, net of Ergomed’s discount, approximately $4.9 million and $1.7 million, respectively, as research and development expense related to Ergomed’s services.

In October 2013, the Company entered into two co-development and profit sharing agreements with Ergomed. One agreement supports the Phase I study being conducted at the Naval Medical Center, San Diego under a Cooperative Research and Development Agreement (CRADA) with the U.S. Navy for the development of Multikine as a potential treatment in HIV/HPV co-infected men and women with peri-anal warts. The other agreement focuses on the development of Multikine in HIV/HPV co-infected women with cervical dysplasia. Ergomed will assume up to $3 million in clinical and regulatory costs for each study.

On October 31, 2013, the Company commenced arbitration proceedings against inVentiv Health Clinical, LLC, or inVentiv, the Company’s former clinical research organization (CRO). The arbitration claim, initiated under the Commercial Rules of the American Arbitration Association, alleges (i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud. Currently, the Company is seeking at least $50 million in damages in its amended statement of claim. Based upon further analysis, however, the Company believes that its damages (direct and consequential) presently total over $150 million.

On December 12, 2013, the former CRO filed a counterclaim, alleging breach of contract on the part of CEL-SCI and seeking at least $2 million in damages. On December 20, 2013, the former CRO moved to dismiss certain claims. On June 24, 2014, the arbitrator denied the motion to dismiss.

In an amended statement of claim, the Company asserted the claims set forth above as well as an additional claim for professional malpractice. The arbitrator subsequently granted inVentiv’s motion to dismiss the professional malpractice claim based on the “economic loss doctrine” under New Jersey law, a legal doctrine that, under certain circumstances, prohibits bringing a negligence-based claim alongside a claim for breach of contract. The arbitrator denied the remainder of inVentiv’s motion, which had sought to dismiss certain other aspects of the amended statement of claim. In particular, the arbitrator rejected inVentiv’s argument that several aspects of the amended statement of claim were beyond the arbitrator’s jurisdiction.

In connection with the pending arbitration proceedings, inVentiv has asserted counterclaims against the Company for (i) breach of contract, seeking at least $2 million in damages for services allegedly performed by inVentiv; (ii) breach of contract, seeking at least $1 million in damages for the Company’s alleged use of inVentiv’s name in connection with publications and promotions in violation of the parties’ contract; (iii) opportunistic breach, restitution and unjust enrichment, seeking at least $20 million in disgorgement of alleged unjust profits allegedly made by the Company as a result of the purported breaches referenced in subsection (ii); and (iv) defamation, seeking at least $1 million in damages for allegedly defamatory statements made about inVentiv. The Company believes inVentiv’s counterclaims are meritless and intends to vigorously defend against them. However, if such defense is unsuccessful, and inVentiv successfully asserts any of its counterclaims, such an adverse determination could have a material adverse effect on the Company’s business, results, financial condition and liquidity.

In October 2015, the Company signed a funding agreement with a company established by Lake Whillans Litigation Finance, LLC, a firm specializing in funding litigation expenses. Pursuant to the agreement, an affiliate of Lake Whillans will provide the Company funding for litigation expenses to support its arbitration claims against inVentiv. The funding is available to the Company as needed to fund the expenses of the ongoing arbitration and will only be repaid when the Company receives proceeds from the arbitration. During the nine months ended June 30, 2016, the Company recognized a gain of approximately $1.1 million on the derecognition of legal fees to record the transfer of the liability that existed prior to the execution of the financing agreement from the Company to Lake Whillans. The gain on derecognition of legal fees is recorded as a reduction of general and administration expenses on the Statement of Operations. All related legal fees are directly billed to and paid by Lake Whillans. As part of the agreement with Lake Whillans, the law firm agreed to cap its fees and expenses for the arbitration at $5 million.

The arbitration hearing on the merits (the “trial”) has been scheduled to commence on September 7, 2016.

Lease Agreements

In August 2007, the Company leased a building near Baltimore, Maryland. The building was remodeled in accordance with the Company’s specifications so that it can be used by the Company to manufacture Multikine for the Company’s Phase 3 clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease.

The Company was required to deposit the equivalent of one year of base rent in accordance with the contract. When the Company meets the minimum cash balance required by the lease, the deposit will be returned to the Company. The $1,670,917 deposit is included in non-current assets at June 30, 2016 and September 30, 2015.

The Company subleases a portion of its rental space on a month to month term lease, which requires a 30 day notice for termination. Effective February 1, 2016, the parties agreed to a 3% rental increase. As of that date, the Company receives $5,628 per month in rent for the subleased space.

The Company leases its research and development laboratory under a 60 month lease which expires February 28, 2017. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight line basis over the full 60 month term of the lease at the rate of approximately $11,000 per month. As of June 30, 2016 and September 30, 2015, the Company has recorded a deferred rent liability of $4,000 and $6,000, respectively.

The Company leases office headquarters under a 60 month lease which expires June 30, 2020. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight line basis over the full 60 month term of the lease at the rate of approximately $8,000 per month. As of June 30, 2016 and September 30, 2015, the Company has recorded a deferred rent liability of $19,000 and $13,000, respectively.

The Company leased office equipment under a capital lease arrangement. The term of the capital lease is 48 months and expires on September 30, 2016. The monthly lease payment is $1,025. The lease bears interest at approximately 6% per annum.

H. PATENTS

During the nine and three months ended June 30, 2016 and 2015, no patent impairment charges were recorded. For the nine and three months ended June 30, 2016, amortization of patent costs totaled approximately $30,000 and $12,000, respectively. For the nine and three months ended June 30, 2015, amortization of patent costs totaled approximately $31,000 and $12,000, respectively. Amortization of patent costs is included in general and administrative expenses on the Statement of Operations. The Company estimates that future amortization expense will be as follows:

Three months ending September 30, 2016	$9,210
Year ending September 30,
2017	36,841
2018	36,507
2019	34,804
2020	31,611
2021	28,311
Thereafter	89,209
Total	$266,493

I. LOSS PER COMMON SHARE

The following tables provide the details of the basic and diluted loss per-share (LPS) computations:

	Nine Months Ended June 30, 2016
	Net Loss	Weighted Average Shares	LPS


Basic and dilutive LPS	$(10,352,366)	117,412,443	$(0.09)

	Three Months Ended June 30, 2016
	Net Loss	Weighted Average Shares	LPS

Basic and dilutive LPS	$(3,849,324)	124,132,500	$(0.03)

	Nine Months Ended June 30, 2015
	Net Loss	Weighted Average Shares	LPS

Basic and dilutive LPS	$(24,830,691)	77,625,511	$(0.32)

	Three Months Ended June 30, 2015
	Net Loss	Weighted Average Shares	LPS

Basic LPS	$(4,429,137)	83,796,311	$(0.05)
Gain on derivatives	(1,100,760)	1,337,796

Dilutive LPS	$(5,529,897)	85,134,107	$(0.06)

In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, Earnings Per Share, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of June 30:

	2016	2015

Options and Warrants	86,066,292	38,786,333
Convertible Debt	-	1,871,283
Unvested Restricted Stock	15,100,000	15,100,000
Total	101,166,292	55,757,616

SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Liquidity and Capital Resources

The Company’s lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), is currently being tested in a Phase 3 clinical trial in advanced primary head and neck cancer. Multikine has been cleared for clinical testing by the regulators in twenty four countries around the world, including the United States. Multikine is also being used in a Phase I study at the Naval Medical Center, San Diego under a CRADA with the U.S. Navy in HIV/HPV co-infected men and women with peri-anal warts.

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this report as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company’s future anticipated regulatory submission for approval. Multikine has not been licensed or approved by the FDA or any other regulatory agency. Neither has its safety or efficacy been established for any use.

The Company also owns and is developing a pre-clinical technology called LEAPS (Ligand Epitope Antigen Presentation System).

All of the Company’s projects are under development. As a result, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

Since inception, the Company has financed its operations through the sale of equity securities, convertible notes, loans and certain research grants. The Company’s expenses will likely exceed its revenues as it continues the development of Multikine and brings other drug candidates into clinical trials. Until such time as the Company becomes profitable, any or all of these financing vehicles or others may be utilized to assist the Company’s capital requirements.

Capital raised by the Company has been expended primarily for patent applications, debt repayment, research and development, administrative costs, and the construction of the Company’s laboratory facilities. The Company does not anticipate realizing significant revenues until it enters into licensing arrangements regarding its technology and know-how or until it receives regulatory approval to sell its products (which could take a number of years). As a result, the Company has been dependent upon the proceeds from the sale of its securities to meet all of its liquidity and capital requirements and anticipates having to do so in the future.

The Company will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes that, counting its cash on hand and access to the capital markets established over the years, it will have enough capital to support its operations through year end. In addition, the Company expects to receive proceeds from the arbitration against its former clinical research organization, InVentiv.

The Company estimates the total remaining cash cost of the Phase 3 trial as currently planned, with the exception of the parts that will be paid by its licensees, Teva Pharmaceuticals and Orient Europharma, to be approximately $14.7 million. This is in addition to approximately $31.9 million which has been paid as of June 30, 2016. This estimate is based on the information currently available in the Company’s contracts with the Clinical Research Organizations responsible for managing the Phase 3 trial. This number can be affected by the speed of enrollment, rate of death of patients, foreign currency exchange rates and many other factors, some of which cannot be foreseen today. It is therefore possible that the cost of the Phase 3 trial will be higher than currently estimated. The trial costs will also increase should the Company need to enroll additional patients to replace patients enrolled by inVentiv, its former clinical research organization, since the data from certain patients enrolled by inVentiv may not be usable, or for other reasons. If additional patients need to be enrolled, the timelines for the trial will also be affected.

In April 2013, the Company announced that it had replaced the CRO running its Phase 3 clinical trial. This was necessary since the patient enrollment in the study dropped off substantially following a takeover of the CRO which caused most of the members of the CRO’s study team to leave the CRO. The Company announced that it had hired two CRO’s who will manage the global Phase 3 study; Aptiv Solutions and Ergomed, which are both international leaders in managing oncology trials. Both CRO’s helped the Company expand the trial to over 80 clinical sites globally. As of June 30, 2016, the study has enrolled 848 patients.

Under a co-development agreement, Ergomed will contribute up to $12 million towards the study where it will perform clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specified maximum amount, only from sales for head and neck cancer. Ergomed, a privately-held firm headquartered in Europe with global operations, has entered into numerous similar co-development agreements, including one with Genzyme (purchased by Sanofi in 2011 for over $20 billion). Ergomed will be responsible for the new patient enrollment.

During the nine months ended June 30, 2016, the Company’s cash decreased by approximately $500,000. Significant components of this decrease include net proceeds from the sale of the Company’s stock of $16.8 million offset by net cash used to fund the Company’s regular operations, including its on-going Phase 3 clinical trial, of $16.2 million and the $1.1 million repayment of the related party loan. During the nine months ended June 30, 2015, the Company’s cash increased by $2.7 million. Significant components of this increase include net proceeds from the sale of the Company’s stock of $21.3 million offset by net cash used to fund the Company’s regular operations, including its on-going Phase 3 clinical trial, of $18.5 million.

In January 2016, the Company sold 3,000,000 shares of its common stock and 3,000,000 Series X Warrants to the de Clara Trust for approximately $1.1 million. Each Series X Warrant allows the de Clara Trust to purchase one share of the Company's common stock at a price of $0.37 per share at any time on or before January 13, 2021.

In February 2016, the Company sold 1,300,000 shares of its common stock and 650,000 Series Y Warrants to a private investor for $624,000. Each Series Y Warrant allows the holder to purchase one share of the Company's common stock at a price of $0.48 per share at any time on or before February 15, 2021.

On May 23, 2016, the Company closed a registered direct offering of 10,000,000 shares of common stock and 6,600,000 Series Z warrants to purchase shares of common stock. The common stock and warrants were sold at a combined per unit price of $0.50 for net proceeds of approximately $4.6 million, net of placement agent’s commissions and offering expenses. The Series Z warrants may be exercised at any time on or after November 23, 2016 and on or before November 23, 2021 at a price of $0.55 per share. The Company issued 500,000 Series ZZ warrants to the placement agent as part of its compensation. The Series ZZ warrants may be exercised at any time on or after November 23, 2016 and on or before May 18, 2021 at a price of $0.55 per share.

Results of Operations and Financial Condition

During the nine and three months ended June 30, 2016, grant and other income decreased by approximately $540,000 and $260,000, respectively, compared to the nine and three months ended June 30, 2015. The decrease is primarily due to the timing of study drug shipments to supply the Company’s partner in Taiwan and the grant income received through the Company’s Small Business Innovation Research (SBIR) grant during the quarter ended June 30, 2015.

During the nine and three months ended June 30, 2016, research and development expenses decreased by approximately $1.1 million and $890,000, respectively, compared to the nine and three months ended June 30, 2015. The Company is continuing the Phase 3 clinical trial and research and development fluctuates based on the activity level of the clinical trial.

During the nine and three months ended June 30, 2016, general and administrative expenses decreased by approximately $7 million and $1.2 million, respectively, compared to the nine and three months ended June 30, 2015. Major components of the decrease are the reduction of legal fees and a decrease in share-based employee compensation costs, during the nine and three months ended June 30, 2016. Additionally, during the nine months ended June 30, 2016 the Company recognized an approximate $1.1 million dollar gain on derecognition of legal fees to record the transfer of the liability from the Company to Lake Whillans that existed prior to the execution of the financing agreement. The gain on derecognition of legal fees is recorded as a reduction of general and administrative expenses.

The gain on derivative instruments of $8 million and $2.5 million, respectively, for the nine months ended June 30, 2016 were the results of the change in fair value of the derivative liabilities during the respective periods. The gain on derivative instruments of $1.8 million and $4.4 million for the nine and three months ended June 30, 2015 was the result of the change in fair value of the derivative liabilities during the period. These changes were caused by fluctuations in the share price of the Company’s common stock.

During the three months ended June 30, 2015, the Company recorded a loss on debt extinguishment of $641,000. This amount was comprised of an approximate $166,000 premium on the note payable held in a related party trust, and an additional expense of approximately $475,000 relating to the modification of Series N warrants also held in the trust. The loss on debt extinguishment resulted from substantive modification of the terms under the note, including an extension of the expiration date and a decrease in the interest rate, and an extension of the expiration date on the warrants.

Net interest income was $49,000 and $25,000 for the nine and three months ended June 30, 2016, which consisted of interest expense on the loan from the Company’s president of approximately $29,000 and $0, respectively, offset by interest income of approximately $78,000 and $25,000, respectively, earned on the Company’s cash balances. Net interest expense was $42,000 and $15,000 for the nine and three months ended June 30, 2015, which consisted of approximately $125,000 and $42,000, respectively, of interest expense primarily on the loan from the Company’s president, offset by approximately $83,000 and $27,000, respectively, of interest income earned on the Company’s cash balances.

Research and Development Expenses

The Company’s research and development efforts involve Multikine and LEAPS. The table below shows the research and development expenses associated with each project.

	Nine months ended June 30,		Three months ended June 30,
	2016	2015	2016	2015

MULTIKINE	$14,344,946	$15,326,179(a)	$4,743,319	$5,593,709(a)
LEAPS	291,251	375,807	94,789	133,868

TOTAL	$14,636,197	$15,701,986	$4,838,108	$5,727,577

(a)

The above Multikine expense amounts include depreciation relating to research and development equipment, which in prior years was included as a separate line item on the Statement of Operations. For the nine and three months ended June 30, 2015, depreciation expenses totaling $119,053, and $35,009, respectively, were reclassified to Multikine research and development expenses to be consistent with the current year presentation.

Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company’s clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all of the Company’s projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

Critical Accounting Estimates and Policies

Management’s discussion and analysis of the Company’s financial condition and results of operations is based on its unaudited condensed financial statements. The preparation of these financial statements is based on the selection of accounting policies and the application of significant accounting estimates, some of which require management to make judgments, estimates and assumptions that affect the amounts reported in the financial statements and notes. The Company believes some of the more critical estimates and policies that affect its financial condition and results of operations are in the areas of operating leases and stock-based compensation. For more information regarding the Company’s critical accounting estimates and policies, see Part II, Item 7 of the Company’s Annual Report on Form 10-K for the year ended September 30, 2015. The application of these critical accounting policies and estimates has been discussed with the Audit Committee of the Company’s Board of Directors.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

The Company had a loan from its president that bore interest at 9%. This loan was paid on January 12, 2016. The Company does not believe that it has any significant exposures to market risk.

Item 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the direction and with the participation of the Company’s management, including the Company’s Chief Executive and Chief Financial Officer, the Company has conducted an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of June 30, 2016. The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and that such information is accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. The Company’s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching its desired disclosure control objectives. Based on the evaluation, the Chief Executive and Chief Financial Officer has concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2016.

Changes in Internal Control over Financial Reporting

The Company’s management, with the participation of the Chief Executive and Chief Financial Officer, has evaluated whether any change in the Company’s internal control over financial reporting occurred during the first nine months of fiscal year 2016. There was no change in the Company’s internal control over financial reporting during the nine months ended June 30, 2016.

PART II

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Issuance of Restricted Stock

During the nine months ended June 30, 2016 the Company issued 647,000 restricted shares of common stock to consultants for investor relations services from the Stock Bonus Plans.

The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 with respect to the issuance of these shares. The individuals who acquired these shares were sophisticated investors and were provided full information regarding the Company’s business and operations. There was no general solicitation in connection with the offer or sale of these securities. The individuals who acquired these shares acquired them for their own accounts. The certificates representing these shares bear a restricted legend providing that they cannot be sold except pursuant to an effective registration statement or an exemption from registration. No commission or other form of remuneration was given to any person in connection with the issuance of these shares.

Item 6. (a) Exhibits

Number Exhibit

31 Rule 13a-14(a) Certifications

32 Section 1350 Certifications

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CEL-SCI CORPORATION

Date: August 9, 2016	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Executive Officer*

* Also signing in the capacity of the Principal Accounting and Financial Officer.

EX-31.1 2 cvm_ex311.htm CERTIFICATION Blueprint

Exhibit 31.1

CERTIFICATIONS

I, Geert Kersten, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or cause such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have significant role in the registrant’s internal control over financial reporting.



August 9, 2016	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Executive Officer

EX-31.2 3 cvm_ex312.htm CERTIFICATION Blueprint

Exhibit 31.2

CERTIFICATIONS

I, Geert Kersten, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;

b) any fraud, whether or not material, that involves management or other employees who have significant role in the registrant’s internal control over financial reporting.



August 9, 2016	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Financial Officer

EX-32 4 cvm_ex32.htm CERTIFICATE Blueprint

Exhibit 32

In connection with the Quarterly Report of CEL-SCI Corporation (the “Company”) on Form 10-Q for the period ending June 30, 2016 as filed with the Securities and Exchange Commission (the “Report”), Geert Kersten, the Principal Executive and Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of the Company.



August 9, 2016	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Executive and Principal Financial Officer

EX-101.INS 5 cvm-20160630.xml XBRL INSTANCE DOCUMENT 0000725363 2014-10-01 2015-06-30 0000725363 2016-06-30 0000725363 2015-10-01 2016-06-30 0000725363 2015-09-30 0000725363 CVM:SeriesWMember 2016-06-30 0000725363 CVM:SeriesVMember 2016-06-30 0000725363 CVM:SeriesPMember 2016-06-30 0000725363 CVM:ConsultantsMember 2016-06-30 0000725363 CVM:SeriesRMember 2016-06-30 0000725363 CVM:Level1Member 2016-06-30 0000725363 CVM:Level1Member 2015-09-30 0000725363 CVM:Level2Member 2016-06-30 0000725363 CVM:Level2Member 2015-09-30 0000725363 CVM:Level3Member 2016-06-30 0000725363 CVM:Level3Member 2015-09-30 0000725363 CVM:TotalMember 2016-06-30 0000725363 CVM:TotalMember 2015-09-30 0000725363 CVM:IncentiveStockOptionPlansMember 2016-06-30 0000725363 CVM:NonQualifiedStockOptionPlansMember 2016-06-30 0000725363 CVM:StockBonusPlansMember 2016-06-30 0000725363 us-gaap:StockCompensationPlanMember 2016-06-30 0000725363 CVM:SeriesNMember 2015-10-01 2016-06-30 0000725363 CVM:SeriesRMember 2015-10-01 2016-06-30 0000725363 CVM:SeriesPMember 2015-10-01 2016-06-30 0000725363 CVM:ConsultantsMember 2015-10-01 2016-06-30 0000725363 CVM:SeriesNMember 2015-09-30 0000725363 CVM:SeriesQMember 2015-09-30 0000725363 CVM:SeriesRMember 2015-09-30 0000725363 2014-09-30 0000725363 CVM:ConsultantsMember 2015-09-30 0000725363 CVM:SeriesSMember 2016-06-30 0000725363 CVM:SeriesSMember 2015-10-01 2016-06-30 0000725363 CVM:SeriesUMember 2016-06-30 0000725363 CVM:SeriesUMember 2015-10-01 2016-06-30 0000725363 CVM:SeriesVMember 2015-10-01 2016-06-30 0000725363 CVM:IncentiveStockBonusPlansMember 2016-06-30 0000725363 2014-10-01 2015-09-30 0000725363 2016-04-01 2016-06-30 0000725363 2015-04-01 2015-06-30 0000725363 2015-06-30 0000725363 CVM:IncentiveStockOptionPlansMember 2015-09-30 0000725363 CVM:NonQualifiedStockOptionPlansMember 2015-09-30 0000725363 CVM:StockBonusPlansMember 2015-09-30 0000725363 us-gaap:StockCompensationPlanMember 2015-09-30 0000725363 CVM:IncentiveStockBonusPlansMember 2015-09-30 0000725363 CVM:SeriesSMember 2015-09-30 0000725363 CVM:SeriesUMember 2015-09-30 0000725363 CVM:SeriesVMember 2015-09-30 0000725363 CVM:SeriesPMember 2015-09-30 0000725363 CVM:SeriesNMember 2014-10-01 2015-09-30 0000725363 CVM:SeriesQMember 2014-10-01 2015-09-30 0000725363 CVM:SeriesRMember 2014-10-01 2015-09-30 0000725363 CVM:SeriesSMember 2014-10-01 2015-09-30 0000725363 CVM:SeriesUMember 2014-10-01 2015-09-30 0000725363 CVM:SeriesVMember 2014-10-01 2015-09-30 0000725363 CVM:SeriesPMember 2014-10-01 2015-09-30 0000725363 CVM:ConsultantsMember 2014-10-01 2015-09-30 0000725363 CVM:SeriesXMember 2016-06-30 0000725363 CVM:SeriesWMember 2015-10-01 2016-06-30 0000725363 CVM:SeriesYMember 2016-06-30 0000725363 CVM:SeriesYMember 2015-10-01 2016-06-30 0000725363 CVM:SeriesNMember 2016-06-30 0000725363 CVM:SeriesXMember 2015-10-01 2016-06-30 0000725363 2016-08-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares CEL SCI CORP 0000725363 10-Q 2016-06-30 false --09-30 No No Yes Accelerated Filer Q3 2016

0.01

200000

0.01

600000000

14480620

15447603

1820917

1970917

3565684 4044473

266493

291564

250552

307466

8576974

8833183

444349

487793

1259458

1401839

150000

713549

979655

790658

87214

4037

9997

1104057

316804

365131

520973

88575

4437389

5128682

5281512

6705470

2309

9028

18378

9026

126501

126639

12823052

13686587

5000

18254443

20532722

14480620

15447603

-3773823

-5085119

-284553845

-274201479

279328561

267992754

1451461

1123606

145146097

112360568

145146097

112360568

1960000

7680000

3594000

3350000

16000000

1960000

7680000

3594000

3350000

16000000

1685966

6005721

1690665

5849103

2562950

1767047

15600000

1643714

1423999

15600000

11334

1062861

1030223

1549905

400000

6635

1219479

1949459

1892950

400000

3930686 7363555 3443038 6278481 3557971 0

3930686

7363555

8892366

6323032

12823052

13686587

8892336

6323032

307894

7174439

8003220

-4605105

-1988082

8/18/2008 12/6/2012 2/10/2012 12/2/11- 10/1/16 10/11/13 -10/24/14 4/17/2014 5/28/2015 8/18/2008 6/21/2012 12/6/2012 10/11/13- 10/24/14 4/17/2014 5/28/2015 2/10/2012 10/14/05 – 7/1/15 10/28/2015 2/15/2016 1/13/2016 17223248 20253164 590001 440000 2625000 2844627 1200000 2625000 238000 25928010 445514 25928010 445514 20253164 590001 3000000 650000 2844627 0.67 0.79 4.5 4 0.53 5 4 1.25 1.75 1.25 1.75 0.79 4.5 0.37 0.48 0.53 0.37 0.66 3.50 20.00 8/18/2017 12/6/2016 3/6/2017 10/27/16- 12/31/18 10/11/2018 10/17/2017 5/28/2020 8/18/2017 12/22/2015 12/6/2016 10/11/2018 10/17/2017 5/28/2020 3/6/2017 10/14/15 - 6/30/18 10/28/20 2/15/2021 1/13/2021 4455 44551 12823052 13686587

5218960

5726682

8513620

11230427

723681

183726

129975

389223

15701986

14636197

4838108

5727577

10978254

3987011

1674614

2863121

26680240

18623208

6512722

8590698

-25956559

-18439482

-6382747

-8201475

1808954

8037974

2508744

4428780

-641276

-41810

49142

24679

-15166

-24830691

-10352366

-3849324

-4429137

-0.32

-0.09

77625511

117412443

437729

618890

163431

118272

4570999

1263662

-123066

-120693

-313

-115

150000

-36513

-142381

283864

-267742

559828 522233

76672

-5854

-1591

-138

-5795

3392

95214

-48327

-117207

86398

1856635

-1079423

-18489770

-16218596

-66038

-36413

9422

5008

56616

31405

21278905

16858029

6290

6685

1104057

21272615

15747287

2716807

-507722

12625 0 0 363298 -140312 -388130 128630 24810 32 34 -975 -12 0 0 0 0 0 -346000 0 346000 -8463957 -7174439 1000 0 20464 1636 8442493 7172803 0

124914

43646

Basis of Presentation   The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Companys annual report on Form 10-K for the year ended September 30, 2015.   In the opinion of management, the accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the Companys financial position as of June 30, 2016 and the results of its operations for the nine and three months then ended. The condensed balance sheet as of September 30, 2015 is derived from the September 30, 2015 audited financial statements. Significant accounting policies have been consistently applied in the interim financial statements and the annual financial statements. The results of operations for the nine and three months ended June 30, 2016 are not necessarily indicative of the results to be expected for the entire year.   Summary of Significant Accounting Policies:   Research and Office Equipment and Leasehold Improvements - Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Research and office equipment are reviewed on a quarterly basis to determine if any of the assets are impaired.   Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made in the period identified. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.   Research and Development Costs - Research and development costs are expensed as incurred.   Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized.  A full valuation allowance was recorded against the deferred tax assets as of June 30, 2016 and September 30, 2015.   Derivative Instruments The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, Accounting for Derivative Instruments and Hedging Activities. In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are remeasured at fair value at the end of each reporting period as long as they are outstanding.   Deferred Rent (Asset) Consideration paid, including deposits, related to operating leases is recorded as a deferred rent asset and amortized as rent expense over the lease term. Interest on deferred rent is calculated at 3% on the funds deposited on the manufacturing facility and is included in deferred rent. This interest income will be used to offset future rent.   Stock-Based Compensation Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 Compensation Stock Compensation. The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period.   Equity instruments issued to non-employees are accounted for in accordance with ASC 505-50, Equity-Based Payments to Non Employees. Accordingly, compensation is recognized when goods or services are received and options issued are measured using the Black-Scholes valuation model. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected life of the options.   The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders.   The Companys stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of daily closing prices of the Companys common stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with term equal to the expected life of the option. Historical data was used to estimate option exercise and employee termination within the valuation model. The expected term of options represents the period of time that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.   Vesting of restricted stock granted under the Incentive Stock Bonus Plan is subject to service, performance and market conditions and meets the classification of equity awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.   Reclassification Certain prior year items have been reclassified to conform to the current year presentation. Such reclassifications include approximately $145,000 between related party notes payable and additional paid-in capital to reflect the modification of the note payable to the de Clara Trust in July 2015, which was accounted for as an extinguishment.

In January 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-01, Financial Instruments Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new guidance is intended to improve the recognition and measurement of financial instruments. The new guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted for specific provisions within the guidance. Management does not expect the new standard to have a material effect on its financial statements and related disclosures.   In February 2016, the FASB issued ASU 2016-02, Leases, which will require most leases (with the exception of leases with terms of less than one year) to be recognized on the balance sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning with the earliest comparative period presented. The Company is currently evaluating the effect of the new standard on its financial statements and related disclosures.   In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 simplifies several aspects of the accounting for share-based payment award transactions, including income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2016 but early adoption is permitted. The Company is currently evaluating the effect of the new amendment on its financial statements and related disclosures.   The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

Stock options, stock bonuses and compensation granted by the Company as of June 30, 2016 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>Name of Plan</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total Shares Reserved Under Plans</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Reserved for Outstanding Options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Issued</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Remaining Options/Shares Under Plans</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 48%">Incentive Stock Options Plans</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,960,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,685,966</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">N/A</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">11,334</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Non-Qualified Stock Option Plans</td> <td> </td> <td> </td> <td style="text-align: right">7,680,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,005,721</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,062,861</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock Bonus Plans</td> <td> </td> <td> </td> <td style="text-align: right">3,594,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,562,950</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,030,223</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock Compensation Plan</td> <td> </td> <td> </td> <td style="text-align: right">3,350,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,767,047</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,549,905</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Incentive Stock Bonus Plan</td> <td> </td> <td> </td> <td style="text-align: right">16,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">15,600,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">400,000</td> <td> </td></tr> </table>      Stock options, stock bonuses and compensation granted by the Company as of September 30, 2015 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>Name of Plan</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total Shares Reserved Under Plans</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Reserved for Outstanding Options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Issued</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Remaining Options/Shares Under Plans</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 48%">Incentive Stock Option Plans</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,960,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,690,665</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">N/A</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">6,635</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Non-Qualified Stock Option Plans</td> <td> </td> <td> </td> <td style="text-align: right">7,680,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,849,103</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,219,479</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Bonus Plans</td> <td> </td> <td> </td> <td style="text-align: right">3,594,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,643,714</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,949,459</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock Compensation Plan</td> <td> </td> <td> </td> <td style="text-align: right">3,350,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,423,999</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,892,950</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Incentive Stock Bonus Plan</td> <td> </td> <td> </td> <td style="text-align: right">16,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">15,600,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">400,000</td> <td> </td></tr> </table>        Stock option activity:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Nine Months Ended June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 72%">Granted</td> <td style="width: 1%"> </td> <td style="width: 0%"> </td> <td style="width: 10%; text-align: right">210,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 0%"> </td> <td style="width: 10%; text-align: right">803,700</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">55,998</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">137,249</td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Three Months Ended June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 72%">Granted</td> <td style="width: 1%"> </td> <td style="width: 0%"> </td> <td style="width: 10%; text-align: right">0</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 0%"> </td> <td style="width: 10%; text-align: right">801,700</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">5,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">27,833</td> <td> </td></tr> </table>   No shares of restricted stock were forfeited from the Incentive Stock Bonus Plan during the nine and three months ended June 30, 2016. During the nine and three months ended June 30, 2015, 100,000 and 0 shares, respectively, of non-vested restricted stock were forfeited.   Stock-Based Compensation Expense   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Nine Months Ended June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 72%">Employees</td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">1,263,662</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">4,570,999</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Non-employees</td> <td> </td> <td>$</td> <td style="text-align: right">618,890</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">437,729</td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Three months Ended June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 72%">Employees</td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">418,562</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">619,145</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Non-employees</td> <td> </td> <td>$</td> <td style="text-align: right">146,830</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">137,600</td> <td> </td></tr> </table>   Employee compensation expense includes the expense related to options issued or vested and restricted stock. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of their service contracts.   Derivative Liabilities, Warrants and Other Options   The following chart presents the derivative liabilities, warrants and other options outstanding during the quarter ended June 30, 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: bottom">Warrant</td> <td> </td> <td style="vertical-align: bottom; text-align: center">Issue Date</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">Shares Issuable upon Exercise of Warrant</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; text-align: center">Expiration Date</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">Refer-ence</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; width: 20%">Series R</td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 20%; text-align: right">12/6/12</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%; text-align: right">2,625,000</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 10%; text-align: right">4.00</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 20%; text-align: right">12/6/16</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%; text-align: right">1</td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="vertical-align: bottom">Series S</td> <td> </td> <td style="vertical-align: bottom; text-align: right">10/11/13 -10/24/14</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">25,928,010</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">1.25</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10/11/18</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series U</td> <td> </td> <td style="vertical-align: bottom; text-align: right">4/17/14</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">445,514</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">1.75</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10/17/17</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series V</td> <td> </td> <td style="vertical-align: bottom; text-align: right">5/28/15</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">20,253,164</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">0.79</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">5/28/20</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series W</td> <td> </td> <td style="vertical-align: bottom; text-align: right">10/28/15</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">17,223,248</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">0.67</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10/28/20</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series Z</td> <td> </td> <td style="vertical-align: bottom; text-align: right">5/23/16</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6,600,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">0.55</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">11/23/21</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series ZZ</td> <td> </td> <td style="vertical-align: bottom; text-align: right">5/23/16</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">500,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">0.55</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">5/18/21</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series X</td> <td> </td> <td style="vertical-align: bottom; text-align: right">1/13/16</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">3,000,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">0.37</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1/13/21</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series Y</td> <td> </td> <td style="vertical-align: bottom; text-align: right">2/15/16</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">650,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">0.48</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2/15/21</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series N</td> <td> </td> <td style="vertical-align: bottom; text-align: right">8/18/08</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2,844,627</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">0.53</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">8/18/17</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series P</td> <td> </td> <td style="vertical-align: bottom; text-align: right">2/10/12</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">590,001</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">4.50</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">3/6/17</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Consultants</td> <td> </td> <td style="vertical-align: bottom; text-align: right">12/2/11- 1/1/16</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">440,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">0.37- $3.50</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10/27/16- 12/31/18</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">3</td> <td style="vertical-align: bottom"> </td></tr> </table>     The following chart presents the derivative liabilities, warrants and other options outstanding at September 30, 2015:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: bottom">Warrant</td> <td> </td> <td style="vertical-align: bottom; text-align: center">Issue Date</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">Shares Issuable upon Exercise of Warrants</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; text-align: center">Expiration Date</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">Refer-ence</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series N</td> <td> </td> <td style="vertical-align: bottom; text-align: right">8/18/08</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2,844,627</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">0.53</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">8/18/17</td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; width: 20%">Series Q</td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 20%; text-align: right">6/21/12</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%; text-align: right">1,200,000</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%; text-align: right">5.00</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 20%; text-align: right">12/22/15</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%; text-align: right">1</td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="vertical-align: bottom">Series R</td> <td> </td> <td style="vertical-align: bottom; text-align: right">12/6/12</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2,625,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">4.00</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">12/6/16</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series S</td> <td> </td> <td style="vertical-align: bottom; text-align: right">10/11/13- 10/24/14</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">25,928,010</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1.25</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10/11/18</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series U</td> <td> </td> <td style="vertical-align: bottom; text-align: right">4/17/14</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">445,514</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1.75</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10/17/17</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series V</td> <td> </td> <td style="vertical-align: bottom; text-align: right">5/28/15</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">20,253,164</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">0.79</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">5/28/20</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series P</td> <td> </td> <td style="vertical-align: bottom; text-align: right">2/10/12</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">590,001</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">4.50</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">3/6/17</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Consultants</td> <td> </td> <td style="vertical-align: bottom; text-align: right">10/14/05 7/1/15</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">238,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">0.66 20.00</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10/14/15 - 6/30/18</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">3</td> <td style="vertical-align: bottom"> </td></tr> </table>   <table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr> <td style="vertical-align: top; width: 48px; padding: 0.75pt">1.</td> <td style="padding: 0.75pt; text-decoration: underline; text-align: justify">Derivative Liabilities</td></tr> </table>   The table below presents the derivative instruments and their respective balances at the balance sheet dates:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">June 30, 2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%">Series S warrants</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">3,930,686</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">7,363,555</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Series U warrants</td> <td> </td> <td> </td> <td style="text-align: right">4,455</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">44,551</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series V warrants</td> <td> </td> <td> </td> <td style="text-align: right">3,443,038</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,278,481</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series W warrants</td> <td> </td> <td> </td> <td style="text-align: right">3,557,971</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Z warrants</td> <td> </td> <td> </td> <td style="text-align: right">1,756,982</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series ZZ warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">129,920</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Total derivative liabilities</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">12,823,052</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">13,686,587</td> <td style="padding-bottom: 3pt"> </td></tr> </table>     The gains on the derivative instruments are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Nine Months Ended June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 72%">Series A through E warrants</td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">6,105</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series H warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">12,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Q warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">12,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series R warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">131,250</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series S warrants</td> <td> </td> <td> </td> <td style="text-align: right">3,432,869</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">472,487</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series U warrants</td> <td> </td> <td> </td> <td style="text-align: right">40,096</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">74,352</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series V warrants</td> <td> </td> <td> </td> <td style="text-align: right">2,835,443</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,100,760</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series W warrants</td> <td> </td> <td> </td> <td style="text-align: right">1,502,800</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Z warrants</td> <td> </td> <td> </td> <td style="text-align: right">210,848</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series ZZ warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">15,918</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Gain on derivative instruments</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">8,037,974</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">1,808,954</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Three Months Ended June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 72%">Series H warrants</td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">12,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Q warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">12,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series R warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">105,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series S warrants</td> <td> </td> <td> </td> <td style="text-align: right">285,208</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,111,361</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series U warrants</td> <td> </td> <td> </td> <td style="text-align: right">13,366</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">87,659</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series V warrants</td> <td> </td> <td> </td> <td style="text-align: right">1,012,658</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,100,760</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series W warrants</td> <td> </td> <td> </td> <td style="text-align: right">970,746</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Z warrants</td> <td> </td> <td> </td> <td style="text-align: right">210,848</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series ZZ warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">15,918</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Gain on derivative instruments</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">2,508,744</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">4,428,780</td> <td style="padding-bottom: 3pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> </table> The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instruments contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Companys stock because future equity offerings or sales of the Companys stock are not an input to the fair value of a fixed-for-fixed option on equity shares, and equity classification is therefore precluded.   In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting dates is recognized as a gain or loss.   Issuance of additional Warrants   On May 23, 2016, the Company closed a registered direct offering of 10,000,000 shares of common stock and 6,600,000 Series Z warrants to purchase shares of common stock. The common stock and warrants were sold at a combined per unit price of $0.50 for net proceeds of approximately $4.6 million, net of placement agents commissions and offering expenses. The Series Z warrants may be exercised at any time on or after November 23, 2016 and on or before November 23, 2021 at a price of $0.55 per share. The Company also issued 500,000 Series ZZ warrants to the placement agent as part of its compensation. The Series ZZ warrants may be exercised at any time on or after November 23, 2016 and on or before May 18, 2021 at a price of $0.55 per share. The fair value of the Series Z and Series ZZ warrants of $2.1 million on the date of issuance was recorded as a warrant liability.     On October 28, 2015, the Company closed an underwritten public offering of 17,223,248 shares of common stock and 17,223,248 Series W warrants to purchase shares of common stock. The common stock and warrants were sold at a combined per unit price of $0.67 for net proceeds of approximately $10.5 million, net of underwriting discounts and commissions and offering expenses. The Series W warrants are immediately exercisable at a price of $0.67 and expire on October 28, 2020. The fair value of the Series W warrants of $5.1 million on the date of issuance was recorded as warrant liability.   Expiration of Warrants   On December 22, 2015, 1,200,000 Series Q warrants, with an exercise price of $5.00, expired. The fair value of the Series Q warrants was $0 on the date of expiration.   <table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr> <td style="vertical-align: top; width: 48px; padding: 0.75pt">2.</td> <td style="padding: 0.75pt; text-decoration: underline; text-align: justify">Equity-based warrants</td></tr> </table>   In January 2016, the Company sold 3,000,000 shares of its common stock and 3,000,000 Series X warrants to the de Clara Trust for approximately $1.1 million. The de Clara Trust is controlled by Geert Kersten, the Company's Chief Executive Officer and a director. Each Series X warrant allows the de Clara Trust to purchase one share of the Company's common stock at a price of $0.37 per share at any time on or before January 13, 2021. The Series X warrants qualify for equity treatment in accordance with ASC 815. The relative fair value of the warrants was calculated to be approximately $417,000.   In February 2016, the Company sold 1,300,000 shares of its common stock and 650,000 Series Y warrants to a private investor for $624,000. Each Series Y warrant allows the holder to purchase one share of the Company's common stock at a price of $0.48 per share at any time on or before February 15, 2021. The Series Y warrants qualify for equity treatment in accordance with ASC 815. The relative fair value on the date of issuance of the warrants was calculated to be approximately $144,000.   <table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr> <td style="vertical-align: top; width: 48px; padding: 0.75pt">3.</td> <td style="padding: 0.75pt; text-decoration: underline; text-align: justify">Options and shares issued to consultants</td></tr> </table>   The Company typically enters into consulting arrangements in exchange for common stock or stock options. During the nine and three months ended June 30, 2016, the Company issued 990,045 and 186,267 shares of common stock, respectively, of which 647,000 and 67,000, respectively, were restricted shares. Under these arrangements, the common stock was issued with stock prices ranging between $0.37 and $0.72 per share. During the nine and three months ended June 30, 2015, the Company issued 584,476 and 160,492 shares of common stock, respectively, of which 127,000 and 58,000, respectively, were restricted shares. Under these arrangements, the common stock was issued with stock prices ranging between $0.57 and $1.11 per share.   Additionally, during the nine and three months ended June 30, 2016, the Company issued 210,000 and 0 of fully vested options, respectively, to purchase common stock with a fair value ranging between $0.19 and $0.30 per share. During the nine and three months ended June 30, 2015, the Company issued 40,000 and 0 options, respectively, to purchase common stock with a fair value of $0.50 per share. The aggregate values of the issuances of restricted common stock and common stock options are recorded as prepaid expenses and are charged to general and administrative expenses over the periods of service.    During the nine and three months ended June 30, 2016, the Company recorded total expense of approximately $619,000 and $147,000, respectively, relating to these consulting agreements. During the nine and three months ended June 30, 2015, the Company recorded total expense of approximately $438,000 and $138,000, respectively, relating to these consulting agreements. At June 30, 2016 and September 30, 2015, approximately $32,000 and $30,000, respectively, are included in prepaid expenses. As of June 30, 2016, 440,000 vested options issued to consultants as payment for services remained outstanding, all of which were issued from the Non-Qualified Stock Option plans.

In accordance with ASC 820-10, Fair Value Measurements, the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.   ASC 820-10 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:   <table cellpadding="0" style="width: 100%"> <tr> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; padding: 0.75pt">●</td> <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify">Level 1 Observable inputs such as quoted prices in active markets for identical assets or liabilities</td></tr> <tr> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; padding: 0.75pt">●</td> <td colspan="2" style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify">Level 2 Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets</td></tr> </table> <table cellpadding="0" style="width: 100%"> <tr> <td style="vertical-align: top; width: 96px; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif">●</td> <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify; text-indent: -60pt">Level 3 Unobservable inputs that reflect managements assumptions</td></tr> </table>   For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Companys assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.     The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at June 30, 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Other Observable Inputs (Level 2)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Unobservable Inputs (Level 3)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Derivative instruments</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">3,930,686</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">8,892,366</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">12,823,052</td> <td style="padding-bottom: 3pt"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2015:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Other Observable Inputs (Level 2)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Unobservable Inputs (Level 3)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Derivative instruments</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">7,363,555</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">6,323,032</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">13,686,587</td> <td style="padding-bottom: 3pt"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for the nine months ended June 30, 2016 and the year ended September 30, 2015:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">(9 months ended)</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">(12 months ended)</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">June 30, 2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%">Beginning balance</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">6,323,032</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">307,894</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Issuances</td> <td> </td> <td> </td> <td style="text-align: right">7,174,439</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8,003,220</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Realized and unrealized gains</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(4,605,105</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(1,988,082</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td>Ending balance</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">8,892,366</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">6,323,032</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   The fair values of the Companys derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Companys stock, as well as U.S. Treasury Bill rates, are observable in active markets.

On January 12, 2016, the Company owed the de Clara Trust $1,105,989, which amount included accrued and unpaid interest. On January 13, 2016, the de Clara Trust demanded payment on the note payable. At the same time the Company sold 3,000,000 shares of its common stock and 3,000,000 Series X warrants to the de Clara Trust for approximately $1.1 million. Each warrant allows the de Clara Trust to purchase one share of the Company's common stock at a price of $0.37 per share at any time on or before January 13, 2021.   Prior to the repayment, on June 29, 2015, the Company had extended the maturity date of the note to July 6, 2017, lowered the interest rate from 15% to 9% and changed the conversion price from $4.00 to $0.59, the closing stock price on the previous trading day. The Company determined these modifications to be substantive and accounted for the modification as an extinguishment of the pre-modification note and issuance of the post-modification note. The Company recorded an extinguishment loss and a premium on the note payable of approximately $166,000. The premium was credited to additional paid-in capital.     During the nine and three months ended June 30, 2016, the Company paid approximately $43,000 and $0, respectively, in interest expense to Mr. de Clara. During the nine and three months ended June 30, 2015, the Company paid approximately $124,000 and $41,000, respectively, in interest expense to Mr. de Clara.

The Company has incurred significant costs since its inception in connection with the acquisition of certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities, and clinical trials.  The Company has funded such costs with proceeds from loans and the public and private sale of its common stock.  The Company will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts.  To date, the Company has not generated any revenue from product sales.  The ability of the Company to complete the necessary clinical trials and obtain US Food & Drug Administration (FDA) approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.   The Company is currently running a large multi-national Phase 3 clinical trial for head and neck cancer with its partners TEVA Pharmaceuticals and Orient Europharma. During the nine months ended June 30, 2016, the Company raised $16.8 million in net proceeds from public and private sales of common stock and warrants. To finance the study for the next twelve months and beyond, the Company plans to raise additional capital in the form of corporate partnerships, as well as debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine is a product in the Phase 3 clinical trial stage. However, the operating plan may change as a result of many factors currently unknown to the Company, and the Company may need additional funds sooner than planned. There can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all.  If the Company does not raise the necessary amounts of money, it will either have to slow the development of the Phase 3 clinical trial or even significantly curtail its operations until such time as it is able to raise the required funding.   Since the Company launched its Phase 3 clinical trial for Multikine, the Company has spent approximately $31.9 million as of June 30, 2016 on direct costs for the Phase 3 clinical trial.   The financial statements have been prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Companys ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Clinical Research Agreements   In March 2013, the Company entered into an agreement with Aptiv Solutions to provide certain clinical research services in accordance with a master service agreement. The Company will reimburse Aptiv for costs incurred. The agreement required the Company to make $600,000 in advanced payments which are being credited back in $150,000 annual increments through December 2017. As of June 30, 2016, the total balance advanced is $300,000, of which $150,000 is classified as a current asset.   In April 2013, the Company entered into a co-development and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million towards the study in the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. In October 2015 the Company entered into a second co-development and revenue sharing agreement with Ergomed for an additional $2 million, for a total of $12 million. The Company accounted for the co-development and revenue sharing agreement in accordance with ASC 808 Collaborative Arrangements. The Company determined the payments to Ergomed are within the scope of ASC 730 Research and Development. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the Company entered into the co-development and revenue sharing agreement with Ergomed, it has incurred research and development expenses of approximately $17.8 million related to Ergomeds services. This amount is net of Ergomeds discount of approximately $5.9 million. During the nine and three months ended June 30, 2016, the Company recorded, net of Ergomeds discount, approximately $5.9 million and $2.1 million, respectively, as research and development expense related to Ergomeds services. During the nine and three months ended June 30, 2015, the Company recorded, net of Ergomeds discount, approximately $4.9 million and $1.7 million, respectively, as research and development expense related to Ergomeds services.   In October 2013, the Company entered into two co-development and profit sharing agreements with Ergomed.  One agreement supports the Phase I study being conducted at the Naval Medical Center, San Diego under a Cooperative Research and Development Agreement (CRADA) with the U.S. Navy for the development of Multikine as a potential treatment in HIV/HPV co-infected men and women with peri-anal warts.  The other agreement focuses on the development of Multikine in HIV/HPV co-infected women with cervical dysplasia. Ergomed will assume up to $3 million in clinical and regulatory costs for each study.   On October 31, 2013, the Company commenced arbitration proceedings against inVentiv Health Clinical, LLC, or inVentiv, the Companys former clinical research organization (CRO). The arbitration claim, initiated under the Commercial Rules of the American Arbitration Association, alleges (i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud. Currently, the Company is seeking at least $50 million in damages in its amended statement of claim. Based upon further analysis, however, the Company believes that its damages (direct and consequential) presently total over $150 million.      On December 12, 2013, the former CRO filed a counterclaim, alleging breach of contract on the part of CEL-SCI and seeking at least $2 million in damages. On December 20, 2013, the former CRO moved to dismiss certain claims. On June 24, 2014, the arbitrator denied the motion to dismiss.   In an amended statement of claim, the Company asserted the claims set forth above as well as an additional claim for professional malpractice.  The arbitrator subsequently granted inVentivs motion to dismiss the professional malpractice claim based on the economic loss doctrine under New Jersey law, a legal doctrine that, under certain circumstances, prohibits bringing a negligence-based claim alongside a claim for breach of contract.  The arbitrator denied the remainder of inVentivs motion, which had sought to dismiss certain other aspects of the amended statement of claim.  In particular, the arbitrator rejected inVentivs argument that several aspects of the amended statement of claim were beyond the arbitrators jurisdiction.   In connection with the pending arbitration proceedings, inVentiv has asserted counterclaims against the Company for (i) breach of contract, seeking at least $2 million in damages for services allegedly performed by inVentiv; (ii) breach of contract, seeking at least $1 million in damages for the Companys alleged use of inVentivs name in connection with publications and promotions in violation of the parties contract; (iii) opportunistic breach, restitution and unjust enrichment, seeking at least $20 million in disgorgement of alleged unjust profits allegedly made by the Company as a result of the purported breaches referenced in subsection (ii); and (iv) defamation, seeking at least $1 million in damages for allegedly defamatory statements made about inVentiv. The Company believes inVentivs counterclaims are meritless and intends to vigorously defend against them. However, if such defense is unsuccessful, and inVentiv successfully asserts any of its counterclaims, such an adverse determination could have a material adverse effect on the Companys business, results, financial condition and liquidity.   In October 2015, the Company signed a funding agreement with a company established by Lake Whillans Litigation Finance, LLC, a firm specializing in funding litigation expenses. Pursuant to the agreement, an affiliate of Lake Whillans will provide the Company funding for litigation expenses to support its arbitration claims against inVentiv. The funding is available to the Company as needed to fund the expenses of the ongoing arbitration and will only be repaid when the Company receives proceeds from the arbitration. During the nine months ended June 30, 2016, the Company recognized a gain of approximately $1.1 million on the derecognition of legal fees to record the transfer of the liability that existed prior to the execution of the financing agreement from the Company to Lake Whillans. The gain on derecognition of legal fees is recorded as a reduction of general and administration expenses on the Statement of Operations. All related legal fees are directly billed to and paid by Lake Whillans. As part of the agreement with Lake Whillans, the law firm agreed to cap its fees and expenses for the arbitration at $5 million.   The arbitration hearing on the merits (the trial) has been scheduled to commence on September 7, 2016.     Lease Agreements   In August 2007, the Company leased a building near Baltimore, Maryland. The building was remodeled in accordance with the Companys specifications so that it can be used by the Company to manufacture Multikine for the Companys Phase 3 clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease.   The Company was required to deposit the equivalent of one year of base rent in accordance with the contract. When the Company meets the minimum cash balance required by the lease, the deposit will be returned to the Company. The $1,670,917 deposit is included in non-current assets at June 30, 2016 and September 30, 2015.   The Company subleases a portion of its rental space on a month to month term lease, which requires a 30 day notice for termination. Effective February 1, 2016, the parties agreed to a 3% rental increase. As of that date, the Company receives $5,628 per month in rent for the subleased space.   The Company leases its research and development laboratory under a 60 month lease which expires February 28, 2017. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight line basis over the full 60 month term of the lease at the rate of approximately $11,000 per month. As of June 30, 2016 and September 30, 2015, the Company has recorded a deferred rent liability of $4,000 and $6,000, respectively.   The Company leases office headquarters under a 60 month lease which expires June 30, 2020. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight line basis over the full 60 month term of the lease at the rate of approximately $8,000 per month. As of June 30, 2016 and September 30, 2015, the Company has recorded a deferred rent liability of $19,000 and $13,000, respectively.   The Company leased office equipment under a capital lease arrangement. The term of the capital lease is 48 months and expires on September 30, 2016. The monthly lease payment is $1,025. The lease bears interest at approximately 6% per annum.

During the nine and three months ended June 30, 2016 and 2015, no patent impairment charges were recorded. For the nine and three months ended June 30, 2016, amortization of patent costs totaled approximately $30,000 and $12,000, respectively. For the nine and three months ended June 30, 2015, amortization of patent costs totaled approximately $31,000 and $12,000, respectively. Amortization of patent costs is included in general and administrative expenses on the Statement of Operations. The Company estimates that future amortization expense will be as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 87%">Three months ending September 30, 2016</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">9,210</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Year ending September 30,</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2017</td> <td> </td> <td> </td> <td style="text-align: right">36,841</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2018</td> <td> </td> <td> </td> <td style="text-align: right">36,507</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2019</td> <td> </td> <td> </td> <td style="text-align: right">34,804</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2020</td> <td> </td> <td> </td> <td style="text-align: right">31,611</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2021</td> <td> </td> <td> </td> <td style="text-align: right">28,311</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Thereafter</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">89,209</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Total</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">266,493</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

The following tables provide the details of the basic and diluted loss per-share (LPS) computations:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">Nine Months Ended June 30, 2016</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Net Loss</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">LPS</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Basic and dilutive LPS</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">(10,352,366</td> <td style="padding-bottom: 3pt">)</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double"> </td> <td style="border-bottom: black 1.5pt double; text-align: right">117,412,443</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">(0.09</td> <td style="padding-bottom: 3pt">)</td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">Three Months Ended June 30, 2016</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Net Loss</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">LPS</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Basic and dilutive LPS</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">(3,849,324</td> <td style="padding-bottom: 3pt">)</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double"> </td> <td style="border-bottom: black 1.5pt double; text-align: right">124,132,500</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">(0.03</td> <td style="padding-bottom: 3pt">)</td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">Nine Months Ended June 30, 2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Net Loss</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">LPS</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Basic and dilutive LPS</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">(24,830,691</td> <td style="padding-bottom: 3pt">)</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double"> </td> <td style="border-bottom: black 1.5pt double; text-align: right">77,625,511</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">(0.32</td> <td style="padding-bottom: 3pt">)</td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">Three Months Ended June 30, 2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Net Loss</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">LPS</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 58%; text-align: justify">Basic LPS</td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 0%; border-bottom: black 1.5pt double">$</td> <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right">(4,429,137</td> <td style="width: 1%; padding-bottom: 3pt">)</td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 0%; border-bottom: black 1.5pt double"> </td> <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right">83,796,311</td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 0%; border-bottom: black 1.5pt double">$</td> <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right">(0.05</td> <td style="padding-bottom: 3pt">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Gain on derivatives</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(1,100,760</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,337,796</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Dilutive LPS</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">(5,529,897</td> <td style="padding-bottom: 3pt">)</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double"> </td> <td style="border-bottom: black 1.5pt double; text-align: right">85,134,107</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">(0.06</td> <td style="padding-bottom: 3pt">)</td></tr> </table>     21     In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, Earnings Per Share, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of June 30:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%">Options and Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">86,066,292</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">38,786,333</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Convertible Debt</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,871,283</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Unvested Restricted Stock</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">15,100,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">15,100,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Total</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double"> </td> <td style="border-bottom: black 1.5pt double; text-align: right">101,166,292</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double"> </td> <td style="border-bottom: black 1.5pt double; text-align: right">55,757,616</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.

The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Companys annual report on Form 10-K for the year ended September 30, 2015.   In the opinion of management, the accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the Companys financial position as of June 30, 2016 and the results of its operations for the nine and three months then ended. The condensed balance sheet as of September 30, 2015 is derived from the September 30, 2015 audited financial statements. Significant accounting policies have been consistently applied in the interim financial statements and the annual financial statements. The results of operations for the nine and three months ended June 30, 2016 are not necessarily indicative of the results to be expected for the entire year.

Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Research and office equipment are reviewed on a quarterly basis to determine if any of the assets are impaired.

Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made in the period identified. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Research and development costs are expensed as incurred.

The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized.  A full valuation allowance was recorded against the deferred tax assets as of June 30, 2016 and September 30, 2015.

The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, Accounting for Derivative Instruments and Hedging Activities. In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are remeasured at fair value at the end of each reporting period as long as they are outstanding.

Consideration paid, including deposits, related to operating leases is recorded as a deferred rent asset and amortized as rent expense over the lease term. Interest on deferred rent is calculated at 3% on the funds deposited on the manufacturing facility and is included in deferred rent. This interest income will be used to offset future rent.

Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 Compensation Stock Compensation. The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period.   Equity instruments issued to non-employees are accounted for in accordance with ASC 505-50, Equity-Based Payments to Non Employees. Accordingly, compensation is recognized when goods or services are received and options issued are measured using the Black-Scholes valuation model. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected life of the options.   The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders.   The Companys stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of daily closing prices of the Companys common stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with term equal to the expected life of the option. Historical data was used to estimate option exercise and employee termination within the valuation model. The expected term of options represents the period of time that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.   Vesting of restricted stock granted under the Incentive Stock Bonus Plan is subject to service, performance and market conditions and meets the classification of equity awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.

Certain prior year items have been reclassified to conform to the current year presentation. Such reclassifications include approximately $145,000 between related party notes payable and additional paid-in capital to reflect the modification of the note payable to the de Clara Trust in July 2015, which was accounted for as an extinguishment. Stock options, stock bonuses and compensation granted by the Company as of June 30, 2016 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>Name of Plan</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total Shares Reserved Under Plans</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Reserved for Outstanding Options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Issued</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Remaining Options/Shares Under Plans</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 48%">Incentive Stock Options Plans</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,960,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,685,966</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">N/A</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">11,334</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Non-Qualified Stock Option Plans</td> <td> </td> <td> </td> <td style="text-align: right">7,680,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,005,721</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,062,861</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock Bonus Plans</td> <td> </td> <td> </td> <td style="text-align: right">3,594,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,562,950</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,030,223</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock Compensation Plan</td> <td> </td> <td> </td> <td style="text-align: right">3,350,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,767,047</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,549,905</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Incentive Stock Bonus Plan</td> <td> </td> <td> </td> <td style="text-align: right">16,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">15,600,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">400,000</td> <td> </td></tr> </table>      Stock options, stock bonuses and compensation granted by the Company as of September 30, 2015 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>Name of Plan</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total Shares Reserved Under Plans</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Reserved for Outstanding Options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Issued</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Remaining Options/Shares Under Plans</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 48%">Incentive Stock Option Plans</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,960,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,690,665</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">N/A</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">6,635</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Non-Qualified Stock Option Plans</td> <td> </td> <td> </td> <td style="text-align: right">7,680,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,849,103</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,219,479</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Bonus Plans</td> <td> </td> <td> </td> <td style="text-align: right">3,594,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,643,714</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,949,459</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock Compensation Plan</td> <td> </td> <td> </td> <td style="text-align: right">3,350,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,423,999</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,892,950</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Incentive Stock Bonus Plan</td> <td> </td> <td> </td> <td style="text-align: right">16,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">15,600,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">400,000</td> <td> </td></tr> </table>     Stock option activity:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Nine Months Ended June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 72%">Granted</td> <td style="width: 1%"> </td> <td style="width: 0%"> </td> <td style="width: 10%; text-align: right">210,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 0%"> </td> <td style="width: 10%; text-align: right">803,700</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">55,998</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">137,249</td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Three Months Ended June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 72%">Granted</td> <td style="width: 1%"> </td> <td style="width: 0%"> </td> <td style="width: 10%; text-align: right">0</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 0%"> </td> <td style="width: 10%; text-align: right">801,700</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">5,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">27,833</td> <td> </td></tr> </table>   No shares of restricted stock were forfeited from the Incentive Stock Bonus Plan during the nine and three months ended June 30, 2016. During the nine and three months ended June 30, 2015, 100,000 and 0 shares, respectively, of non-vested restricted stock were forfeited.

Stock-Based Compensation Expense   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Nine Months Ended June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 72%">Employees</td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">1,263,662</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">4,570,999</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Non-employees</td> <td> </td> <td>$</td> <td style="text-align: right">618,890</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">437,729</td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Three months Ended June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 72%">Employees</td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">418,562</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">619,145</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Non-employees</td> <td> </td> <td>$</td> <td style="text-align: right">146,830</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">137,600</td> <td> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: bottom">Warrant</td> <td> </td> <td style="vertical-align: bottom; text-align: center">Issue Date</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">Shares Issuable upon Exercise of Warrant</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; text-align: center">Expiration Date</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">Refer-ence</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; width: 20%">Series R</td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 20%; text-align: right">12/6/12</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%; text-align: right">2,625,000</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 10%; text-align: right">4.00</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 20%; text-align: right">12/6/16</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%; text-align: right">1</td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="vertical-align: bottom">Series S</td> <td> </td> <td style="vertical-align: bottom; text-align: right">10/11/13 -10/24/14</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">25,928,010</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">1.25</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10/11/18</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series U</td> <td> </td> <td style="vertical-align: bottom; text-align: right">4/17/14</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">445,514</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">1.75</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10/17/17</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series V</td> <td> </td> <td style="vertical-align: bottom; text-align: right">5/28/15</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">20,253,164</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">0.79</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">5/28/20</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series W</td> <td> </td> <td style="vertical-align: bottom; text-align: right">10/28/15</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">17,223,248</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">0.67</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10/28/20</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series Z</td> <td> </td> <td style="vertical-align: bottom; text-align: right">5/23/16</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6,600,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">0.55</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">11/23/21</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series ZZ</td> <td> </td> <td style="vertical-align: bottom; text-align: right">5/23/16</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">500,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">0.55</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">5/18/21</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series X</td> <td> </td> <td style="vertical-align: bottom; text-align: right">1/13/16</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">3,000,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">0.37</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1/13/21</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series Y</td> <td> </td> <td style="vertical-align: bottom; text-align: right">2/15/16</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">650,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">0.48</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2/15/21</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series N</td> <td> </td> <td style="vertical-align: bottom; text-align: right">8/18/08</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2,844,627</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">0.53</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">8/18/17</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series P</td> <td> </td> <td style="vertical-align: bottom; text-align: right">2/10/12</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">590,001</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">4.50</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">3/6/17</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Consultants</td> <td> </td> <td style="vertical-align: bottom; text-align: right">12/2/11- 1/1/16</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">440,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">0.37- $3.50</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10/27/16- 12/31/18</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">3</td> <td style="vertical-align: bottom"> </td></tr> </table>     11      The following chart presents the derivative liabilities, warrants and other options outstanding at September 30, 2015:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: bottom">Warrant</td> <td> </td> <td style="vertical-align: bottom; text-align: center">Issue Date</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">Shares Issuable upon Exercise of Warrants</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; text-align: center">Expiration Date</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">Refer-ence</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series N</td> <td> </td> <td style="vertical-align: bottom; text-align: right">8/18/08</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2,844,627</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">0.53</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">8/18/17</td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; width: 20%">Series Q</td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 20%; text-align: right">6/21/12</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%; text-align: right">1,200,000</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%; text-align: right">5.00</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 20%; text-align: right">12/22/15</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%; text-align: right">1</td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="vertical-align: bottom">Series R</td> <td> </td> <td style="vertical-align: bottom; text-align: right">12/6/12</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2,625,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">4.00</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">12/6/16</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series S</td> <td> </td> <td style="vertical-align: bottom; text-align: right">10/11/13- 10/24/14</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">25,928,010</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1.25</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10/11/18</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series U</td> <td> </td> <td style="vertical-align: bottom; text-align: right">4/17/14</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">445,514</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1.75</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10/17/17</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series V</td> <td> </td> <td style="vertical-align: bottom; text-align: right">5/28/15</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">20,253,164</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">0.79</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">5/28/20</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Series P</td> <td> </td> <td style="vertical-align: bottom; text-align: right">2/10/12</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">590,001</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">4.50</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">3/6/17</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom">Consultants</td> <td> </td> <td style="vertical-align: bottom; text-align: right">10/14/05 7/1/15</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">238,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">0.66 20.00</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10/14/15 - 6/30/18</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">3</td> <td style="vertical-align: bottom"> </td></tr> </table> The table below presents the derivative instruments and their respective balances at the balance sheet dates:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">June 30, 2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%">Series S warrants</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">3,930,686</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">7,363,555</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Series U warrants</td> <td> </td> <td> </td> <td style="text-align: right">4,455</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">44,551</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series V warrants</td> <td> </td> <td> </td> <td style="text-align: right">3,443,038</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,278,481</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series W warrants</td> <td> </td> <td> </td> <td style="text-align: right">3,557,971</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Z warrants</td> <td> </td> <td> </td> <td style="text-align: right">1,756,982</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series ZZ warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">129,920</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Total derivative liabilities</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">12,823,052</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">13,686,587</td> <td style="padding-bottom: 3pt"> </td></tr> </table> The gains on the derivative instruments are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Nine Months Ended June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 72%">Series A through E warrants</td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">6,105</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series H warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">12,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Q warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">12,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series R warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">131,250</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series S warrants</td> <td> </td> <td> </td> <td style="text-align: right">3,432,869</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">472,487</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series U warrants</td> <td> </td> <td> </td> <td style="text-align: right">40,096</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">74,352</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series V warrants</td> <td> </td> <td> </td> <td style="text-align: right">2,835,443</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,100,760</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series W warrants</td> <td> </td> <td> </td> <td style="text-align: right">1,502,800</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Z warrants</td> <td> </td> <td> </td> <td style="text-align: right">210,848</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series ZZ warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">15,918</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Gain on derivative instruments</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">8,037,974</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">1,808,954</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Three Months Ended June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 72%">Series H warrants</td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">12,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Q warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">12,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series R warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">105,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series S warrants</td> <td> </td> <td> </td> <td style="text-align: right">285,208</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,111,361</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series U warrants</td> <td> </td> <td> </td> <td style="text-align: right">13,366</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">87,659</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series V warrants</td> <td> </td> <td> </td> <td style="text-align: right">1,012,658</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,100,760</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series W warrants</td> <td> </td> <td> </td> <td style="text-align: right">970,746</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Z warrants</td> <td> </td> <td> </td> <td style="text-align: right">210,848</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series ZZ warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">15,918</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Gain on derivative instruments</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">2,508,744</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">4,428,780</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Other Observable Inputs (Level 2)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Unobservable Inputs (Level 3)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Derivative instruments</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">3,930,686</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">8,892,366</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">12,823,052</td> <td style="padding-bottom: 3pt"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2015:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Other Observable Inputs (Level 2)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Unobservable Inputs (Level 3)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 48%">Derivative instruments</td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 1%; border-bottom: black 1.5pt double">$</td> <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right">7,363,555</td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 1%; border-bottom: black 1.5pt double">$</td> <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right">-</td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 1%; border-bottom: black 1.5pt double">$</td> <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right">6,323,032</td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 1%; border-bottom: black 1.5pt double">$</td> <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right">13,686,587</td> <td style="width: 1%; padding-bottom: 3pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">(9 months ended)</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">(12 months ended)</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">June 30, 2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%">Beginning balance</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">6,323,032</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">307,894</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Issuances</td> <td> </td> <td> </td> <td style="text-align: right">7,174,439</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8,003,220</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Realized and unrealized gains</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(4,605,105</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(1,988,082</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td>Ending balance</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">8,892,366</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">6,323,032</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 87%">Three months ending September 30, 2016</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">9,210</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Year ending September 30,</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2017</td> <td> </td> <td> </td> <td style="text-align: right">36,841</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2018</td> <td> </td> <td> </td> <td style="text-align: right">36,507</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2019</td> <td> </td> <td> </td> <td style="text-align: right">34,804</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2020</td> <td> </td> <td> </td> <td style="text-align: right">31,611</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2021</td> <td> </td> <td> </td> <td style="text-align: right">28,311</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Thereafter</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">89,209</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Total</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">266,493</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%">Options and Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">86,066,292</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">38,786,333</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Convertible Debt</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,871,283</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Unvested Restricted Stock</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">15,100,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">15,100,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Total</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double"> </td> <td style="border-bottom: black 1.5pt double; text-align: right">101,166,292</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double"> </td> <td style="border-bottom: black 1.5pt double; text-align: right">55,757,616</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

803700

210000

801700

137249

55998

5000

27833

4570999

1263662

418562

619145

437729 618890 146830 137600 1756982 0 12000 0 0 12000 6105 0 472487 3432869 285208 3111361 131250 0 0 105000 12000 0 0 12000 0 1502800 970746 0 1100760 2835443 1012658 1100760 74352 40096 13366 87659 0 210848 210848 0

1808954

8037974

2508744

4428780

9210

36841

36507

34804

31611

28311

89209

31000

30000

12000

124000

43000

41000

-24830691

-10352366

-3849324

-4429137

86066292 38786333 0 1871283 15100000 15100000

55757616

101166292

145349718

-0.03

-0.05

-0.03

-0.06

124132500

83796311

129920 0 0 15918 15918 0

-1100760

-5529897

1337796

124132500

85134107

EX-101.SCH 6 cvm-20160630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - STATEMENTS OF OPERATIONS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - B. NEW ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - C. STOCKHOLDERS EQUITY link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - D. FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - E. RELATED PARTY LOAN link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - F. OPERATIONS AND FINANCING link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - G. COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - H. PATENTS link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - I. LOSS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - J. SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - C. STOCKHOLDERS EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - D. FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - H. PATENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - I. LOSS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - C. STOCKHOLDERS EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - C. STOCKHOLDERS EQUITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - C. STOCKHOLDERS EQUITY (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - C. STOCKHOLDERS EQUITY (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - C. STOCKHOLDERS EQUITY (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - E. RELATED PARTY LOAN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - H. PATENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - H. PATENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - I. LOSS PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - I. LOSS PER COMMON SHARE (Details 1) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 cvm-20160630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 cvm-20160630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 cvm-20160630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Series W [Member] Class Of Warrant Or Right [Axis] Series V [Member] Series P [Member] Consultants [Member] Series R [Member] Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) FairValueByFairValueHierarchyLevel [Axis] Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Incentive Stock Option Plans Award Type [Axis] NonQualifiedStockOptionPlansMember Stock Bonus Plans Stock Compensation Plan Series N [Member] Series Q [Member] Series S [Member] Series U [Member] Incentive Stock Bonus Plan IncentiveStockOptionPlansMember StockBonusPlansMember StockCompensationPlanMember Series X [Member] Series Y [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS: Cash and cash equivalents Receivables Prepaid expenses Deposits - current portion Inventory used for R&D and manufacturing Deferred rent - current portion Total current assets RESEARCH AND OFFICE EQUIPMENT, net PATENT COSTS, net DEFERRED RENT - net of current portion DEPOSITS TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable Accrued expenses Due to employees Related party loan Deferred rent - current portion Derivative instruments Lease obligation - current portion Total current liabilities Derivative instruments Deferred revenue Deferred rent - net of current portion Lease obligation - net of current portion Deposits held Total liabilities COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' DEFICIT Preferred stock, $.01 par value--200,000 shares authorized;-0- shares issued and outstanding Common stock, $.01 par value - 600,000,000 shares authorized, 145,146,097 shares and 112,360,568 shares issued and outstanding at June 30, 2016 and September 30, 2015, respectively Additional paid-in capital Accumulated deficit Total stockholders' deficit TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT Assets Accumulated Depreciation and Amortization for Research and Office Equipment and Leasehold Improvements Accumulated Amortization for Patents Stockholders Equity Preferred Stock Shares Par Value Preferred Stock Shares Authorized Preferred Stock Shares Issued Preferred Stock Shares Outstanding Common Stock Shares Par Value Common Stock Shares Authorized Common Stock Shares Issued Common Stock Shares Outstanding Income Statement [Abstract] GRANT INCOME AND OTHER OPERATING EXPENSES: Research and development Depreciation and amortization General & administrative Total operating expenses OPERATING LOSS GAIN ON DERIVATIVE INSTRUMENTS LOSS ON DEBT EXTINGUISHMENT INTEREST INCOME (EXPENSE), NET INTEREST EXPENSE NET LOSS NET LOSS PER COMMON SHARE BASIC DILUTED BASIC and DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING BASIC DILUTED BASIC AND DILUTED Statement [Table] Statement [Line Items] Income Statement Location [Axis] Excluded from research and development expenses Depreciation for research and development excluded from research and development expenses Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Issuance of common stock and options for services Modification of warrants issued to consultants Equity based compensation Common stock contributed to 401(k) plan Impairment loss on abandonment of patents Loss on retired equipment Gain on derivative instruments Loss on debt extinguishment (Increase)/decrease in assets: Receivables Deferred rent Prepaid expenses Inventory used for R&D and manufacturing Deposits Increase/(decrease) in liabilities: Accounts payable Accrued expenses Due to employees Deferred rent liability Deferred revenue Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of equipment Expenditures for patent costs Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock and warrants Proceeds from exercise of warrants Payments on related party loan Payments on obligations under capital lease Net cash provided by financing activities NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS, END OF PERIOD SUPPLEMENTAL DISCLOSURE OF NON-CASH CHANGES [us-gaap:AmortizationOfDeferredPropertyTaxes] ACCOUNTS PAYABLE Increase in receivables Increase in research and office equipment (Decrease) in patent costs Decrease in capital lease obligation Increase in direct financing costs (Increase) in accounts payable Total ACCRUED EXPENSES Increase in receivables (Increase) in accrued expenses Total ADDITIONAL PAID IN CAPITAL (Increase) in derivative liabilities Decrease in common stock Increase in prepaid services Increase in patent costs Decrease in additional paid in capital Total SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION: Cash paid for interest expense Notes to Financial Statements A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Accounting Changes and Error Corrections [Abstract] B. NEW ACCOUNTING PRONOUNCEMENTS C. STOCKHOLDERS' EQUITY Fair Value Disclosures [Abstract] D. FAIR VALUE MEASUREMENTS E. RELATED PARTY LOAN F. OPERATIONS AND FINANCING Commitments and Contingencies Disclosure [Abstract] G. COMMITMENTS AND CONTINGENCIES Accounting Policies [Abstract] H. PATENTS I. LOSS PER COMMON SHARE Subsequent Events [Abstract] J. SUBSEQUENT EVENTS A. Summary Of Significant Accounting Policies Policies EX-101.PRE 10 cvm-20160630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Jun. 30, 2016	Aug. 01, 2016
Document And Entity Information
Entity Registrant Name	CEL SCI CORP
Entity Central Index Key	0000725363
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		145,349,718
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2016

XML 12 R2.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS - USD ($)	Jun. 30, 2016	Sep. 30, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 5,218,960	$ 5,726,682
Receivables	790,658	87,214
Prepaid expenses	713,549	979,655
Deposits - current portion	150,000	150,000
Inventory used for R&D and manufacturing	1,259,458	1,401,839
Deferred rent - current portion	444,349	487,793
Total current assets	8,576,974	8,833,183
RESEARCH AND OFFICE EQUIPMENT, net	250,552	307,466
PATENT COSTS, net	266,493	291,564
DEFERRED RENT - net of current portion	3,565,684	4,044,473
DEPOSITS	1,820,917	1,970,917
TOTAL ASSETS	14,480,620	15,447,603
CURRENT LIABILITIES:
Accounts payable	4,437,389	5,128,682
Accrued expenses	520,973	88,575
Due to employees	316,804	365,131
Related party loan	0	1,104,057
Deferred rent - current portion	4,037	9,997
Lease obligation - current portion	2,309	9,028
Total current liabilities	5,281,512	6,705,470
Derivative instruments	12,823,052	13,686,587
Deferred revenue	126,501	126,639
Deferred rent - net of current portion	18,378	9,026
Deposits held	5,000	5,000
Total liabilities	18,254,443	20,532,722
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Preferred stock, $.01 par value--200,000 shares authorized;-0- shares issued and outstanding	0	0
Common stock, $.01 par value - 600,000,000 shares authorized, 145,146,097 shares and 112,360,568 shares issued and outstanding at June 30, 2016 and September 30, 2015, respectively	1,451,461	1,123,606
Additional paid-in capital	279,328,561	267,992,754
Accumulated deficit	(284,553,845)	(274,201,479)
Total stockholders' deficit	(3,773,823)	(5,085,119)
TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT	$ 14,480,620	$ 15,447,603

XML 13 R3.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2016	Sep. 30, 2015
Stockholders Equity
Preferred Stock Shares Par Value	$ 0.01	$ 0.01
Preferred Stock Shares Authorized	200,000	200,000
Preferred Stock Shares Issued	0	0
Preferred Stock Shares Outstanding	0	0
Common Stock Shares Par Value	$ 0.01	$ 0.01
Common Stock Shares Authorized	600,000,000	600,000,000
Common Stock Shares Issued	145,146,097	112,360,568
Common Stock Shares Outstanding	145,146,097	112,360,568

XML 14 R4.htm IDEA: XBRL DOCUMENT

STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
STATEMENTS OF OPERATIONS - USD ($)	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
GRANT INCOME AND OTHER	$ 129,975	$ 389,223	$ 183,726	$ 723,681
OPERATING EXPENSES:
Research and development	4,838,108	5,727,577	14,636,197	15,701,986
General & administrative	1,674,614	2,863,121	3,987,011	10,978,254
Total operating expenses	6,512,722	8,590,698	18,623,208	26,680,240
OPERATING LOSS	(6,382,747)	(8,201,475)	(18,439,482)	(25,956,559)
GAIN ON DERIVATIVE INSTRUMENTS	2,508,744	4,428,780	8,037,974	1,808,954
LOSS ON DEBT EXTINGUISHMENT	0	(641,276)	0	(641,276)
INTEREST INCOME (EXPENSE), NET	24,679	(15,166)	49,142	(41,810)
NET LOSS	$ (3,849,324)	$ (4,429,137)	$ (10,352,366)	$ (24,830,691)
NET LOSS PER COMMON SHARE
BASIC	$ (0.03)	$ (0.05)
DILUTED	$ (0.03)	$ (0.06)
BASIC and DILUTED			$ (0.09)	$ (0.32)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
BASIC	124,132,500	83,796,311
DILUTED	124,132,500	85,134,107
BASIC AND DILUTED			117,412,443	77,625,511

XML 15 R5.htm IDEA: XBRL DOCUMENT

STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
STATEMENTS OF CASH FLOWS - USD ($)	Jun. 30, 2016	Jun. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (10,352,366)	$ (24,830,691)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	118,272	163,431
Issuance of common stock and options for services	618,890	437,729
Equity based compensation	1,263,662	4,570,999
Common stock contributed to 401(k) plan	120,693	123,066
Loss on retired equipment	115	313
Gain on derivative instruments	(8,037,974)	(1,808,954)
Loss on debt extinguishment	0	641,276
(Increase)/decrease in assets:
Receivables	5,854	(76,672)
Deferred rent	522,233	559,828
Prepaid expenses	267,742	(283,864)
Inventory used for R&D and manufacturing	142,381	36,513
Deposits	150,000	150,000
Increase/(decrease) in liabilities:
Accounts payable	(1,079,423)	1,856,635
Accrued expenses	86,398	(117,207)
Due to employees	(48,327)	95,214
Deferred rent liability	3,392	(5,795)
Deferred revenue	(138)	(1,591)
Net cash used in operating activities	(16,218,596)	(18,489,770)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment	(31,405)	(56,616)
Expenditures for patent costs	(5,008)	(9,422)
Net cash used in investing activities	(36,413)	(66,038)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants	16,858,029	21,278,905
Payments on related party loan	(1,104,057)
Payments on obligations under capital lease	(6,685)	(6,290)
Net cash provided by financing activities	15,747,287	21,272,615
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(507,722)	2,716,807
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	5,726,682	8,513,620
CASH AND CASH EQUIVALENTS, END OF PERIOD	5,218,960	11,230,427
ACCOUNTS PAYABLE
Increase in receivables	363,298	0
Increase in research and office equipment	0	12,625
(Decrease) in patent costs	(12)	(975)
Decrease in capital lease obligation	34	32
Increase in direct financing costs	24,810	128,630
(Increase) in accounts payable	(388,130)	(140,312)
Total	0	0
ACCRUED EXPENSES
Increase in receivables	346,000	0
(Increase) in accrued expenses	(346,000)	0
Total	0	0
ADDITIONAL PAID IN CAPITAL
(Increase) in derivative liabilities	(7,174,439)	(8,463,957)
Decrease in common stock	0	1,000
Increase in prepaid services	1,636	20,464
Decrease in additional paid in capital	7,172,803	8,442,493
Total	0
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Cash paid for interest expense	$ 43,646	$ 124,914

XML 16 R6.htm IDEA: XBRL DOCUMENT

A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Jun. 30, 2016

Notes to Financial Statements

A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Summary of Significant Accounting Policies:

Research and Office Equipment and Leasehold Improvements - Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Research and office equipment are reviewed on a quarterly basis to determine if any of the assets are impaired.

Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made in the period identified. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Research and Development Costs - Research and development costs are expensed as incurred.

Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2016 and September 30, 2015.

Derivative Instruments – The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are remeasured at fair value at the end of each reporting period as long as they are outstanding.

Deferred Rent (Asset) – Consideration paid, including deposits, related to operating leases is recorded as a deferred rent asset and amortized as rent expense over the lease term. Interest on deferred rent is calculated at 3% on the funds deposited on the manufacturing facility and is included in deferred rent. This interest income will be used to offset future rent.

Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation – Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period.

Reclassification – Certain prior year items have been reclassified to conform to the current year presentation. Such reclassifications include approximately $145,000 between related party notes payable and additional paid-in capital to reflect the modification of the note payable to the de Clara Trust in July 2015, which was accounted for as an extinguishment.

XML 17 R7.htm IDEA: XBRL DOCUMENT

B. NEW ACCOUNTING PRONOUNCEMENTS

9 Months Ended

Jun. 30, 2016

Accounting Changes and Error Corrections [Abstract]

B. NEW ACCOUNTING PRONOUNCEMENTS

In January 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new guidance is intended to improve the recognition and measurement of financial instruments. The new guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted for specific provisions within the guidance. Management does not expect the new standard to have a material effect on its financial statements and related disclosures.

In February 2016, the FASB issued ASU 2016-02, Leases, which will require most leases (with the exception of leases with terms of less than one year) to be recognized on the balance sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning with the earliest comparative period presented. The Company is currently evaluating the effect of the new standard on its financial statements and related disclosures.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 simplifies several aspects of the accounting for share-based payment award transactions, including income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2016 but early adoption is permitted. The Company is currently evaluating the effect of the new amendment on its financial statements and related disclosures.

The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6510796

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e725-108305

+ Details

XML 18 R8.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY

9 Months Ended

Jun. 30, 2016

Notes to Financial Statements

C. STOCKHOLDERS' EQUITY

Stock options, stock bonuses and compensation granted by the Company as of June 30, 2016 are as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans

Incentive Stock Options Plans		1,960,000		1,685,966		N/A		11,334
Non-Qualified Stock Option Plans		7,680,000		6,005,721		N/A		1,062,861
Stock Bonus Plans		3,594,000		N/A		2,562,950		1,030,223
Stock Compensation Plan		3,350,000		N/A		1,767,047		1,549,905
Incentive Stock Bonus Plan		16,000,000		N/A		15,600,000		400,000

Stock options, stock bonuses and compensation granted by the Company as of September 30, 2015 are as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans

Incentive Stock Option Plans		1,960,000		1,690,665		N/A		6,635
Non-Qualified Stock Option Plans		7,680,000		5,849,103		N/A		1,219,479
Bonus Plans		3,594,000		N/A		1,643,714		1,949,459
Stock Compensation Plan		3,350,000		N/A		1,423,999		1,892,950
Incentive Stock Bonus Plan		16,000,000		N/A		15,600,000		400,000

Stock option activity:

	Nine Months Ended June 30,
	2016		2015
Granted		210,000		803,700
Forfeited		55,998		137,249

	Three Months Ended June 30,
	2016		2015
Granted		0		801,700
Forfeited		5,000		27,833

Stock-Based Compensation Expense

	Nine Months Ended June 30,
	2016		2015
Employees	$	1,263,662	$	4,570,999
Non-employees	$	618,890	$	437,729

	Three months Ended June 30,
	2016		2015
Employees	$	418,562	$	619,145
Non-employees	$	146,830	$	137,600

Derivative Liabilities, Warrants and Other Options

The following chart presents the derivative liabilities, warrants and other options outstanding during the quarter ended June 30, 2016:

Warrant	Issue Date	Shares Issuable upon Exercise of Warrant		Exercise Price		Expiration Date	Refer-ence

Series R	12/6/12		2,625,000	$	4.00	12/6/16		1
Series S	10/11/13 -10/24/14		25,928,010	$	1.25	10/11/18		1
Series U	4/17/14		445,514	$	1.75	10/17/17		1
Series V	5/28/15		20,253,164	$	0.79	5/28/20		1
Series W	10/28/15		17,223,248	$	0.67	10/28/20		1
Series Z	5/23/16		6,600,000	$	0.55	11/23/21		1
Series ZZ	5/23/16		500,000	$	0.55	5/18/21		1
Series X	1/13/16		3,000,000	$	0.37	1/13/21		2
Series Y	2/15/16		650,000	$	0.48	2/15/21		2
Series N	8/18/08		2,844,627	$	0.53	8/18/17
Series P	2/10/12		590,001	$	4.50	3/6/17
Consultants	12/2/11- 1/1/16		440,000	$	0.37- $3.50	10/27/16- 12/31/18		3

The following chart presents the derivative liabilities, warrants and other options outstanding at September 30, 2015:

Warrant	Issue Date	Shares Issuable upon Exercise of Warrants		Exercise Price		Expiration Date	Refer-ence

Series N	8/18/08		2,844,627		0.53	8/18/17
Series Q	6/21/12		1,200,000		5.00	12/22/15		1
Series R	12/6/12		2,625,000		4.00	12/6/16		1
Series S	10/11/13- 10/24/14		25,928,010		1.25	10/11/18		1
Series U	4/17/14		445,514		1.75	10/17/17		1
Series V	5/28/15		20,253,164		0.79	5/28/20		1
Series P	2/10/12		590,001		4.50	3/6/17
Consultants	10/14/05 – 7/1/15		238,000		0.66 – 20.00	10/14/15 - 6/30/18		3

1.	Derivative Liabilities

The table below presents the derivative instruments and their respective balances at the balance sheet dates:

	June 30, 2016		September 30, 2015
Series S warrants	$	3,930,686	$	7,363,555
Series U warrants		4,455		44,551
Series V warrants		3,443,038		6,278,481
Series W warrants		3,557,971		-
Series Z warrants		1,756,982		-
Series ZZ warrants		129,920		-

Total derivative liabilities	$	12,823,052	$	13,686,587

The gains on the derivative instruments are as follows:

	Nine Months Ended June 30,
	2016		2015
Series A through E warrants	$	-	$	6,105
Series H warrants		-		12,000
Series Q warrants		-		12,000
Series R warrants		-		131,250
Series S warrants		3,432,869		472,487
Series U warrants		40,096		74,352
Series V warrants		2,835,443		1,100,760
Series W warrants		1,502,800		-
Series Z warrants		210,848		-
Series ZZ warrants		15,918		-

Gain on derivative instruments	$	8,037,974	$	1,808,954

	Three Months Ended June 30,
	2016		2015
Series H warrants	$	-	$	12,000
Series Q warrants		-		12,000
Series R warrants		-		105,000
Series S warrants		285,208		3,111,361
Series U warrants		13,366		87,659
Series V warrants		1,012,658		1,100,760
Series W warrants		970,746
Series Z warrants		210,848		-
Series ZZ warrants		15,918		-

Gain on derivative instruments	$	2,508,744	$	4,428,780

Issuance of additional Warrants

Expiration of Warrants

On December 22, 2015, 1,200,000 Series Q warrants, with an exercise price of $5.00, expired. The fair value of the Series Q warrants was $0 on the date of expiration.

2.	Equity-based warrants

3.	Options and shares issued to consultants

XML 19 R9.htm IDEA: XBRL DOCUMENT

D. FAIR VALUE MEASUREMENTS

9 Months Ended

Jun. 30, 2016

Fair Value Disclosures [Abstract]

D. FAIR VALUE MEASUREMENTS

In accordance with ASC 820-10, “Fair Value Measurements,” the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.

●	Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities
●	Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets

●	Level 3 – Unobservable inputs that reflect management’s assumptions

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at June 30, 2016:

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total

Derivative instruments	$	3,930,686	$	-	$	8,892,366	$	12,823,052

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2015:

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total

Derivative instruments	$	7,363,555	$	-	$	6,323,032	$	13,686,587

	(9 months ended)			(12 months ended)
	June 30, 2016			September 30, 2015
Beginning balance	$	6,323,032		$	307,894
Issuances		7,174,439			8,003,220
Realized and unrealized gains		(4,605,105	)		(1,988,082	)
Ending balance	$	8,892,366		$	6,323,032

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 20 R10.htm IDEA: XBRL DOCUMENT

E. RELATED PARTY LOAN

9 Months Ended

Jun. 30, 2016

Notes to Financial Statements

E. RELATED PARTY LOAN

XML 21 R11.htm IDEA: XBRL DOCUMENT

F. OPERATIONS AND FINANCING

9 Months Ended

Jun. 30, 2016

Notes to Financial Statements

F. OPERATIONS AND FINANCING

Since the Company launched its Phase 3 clinical trial for Multikine, the Company has spent approximately $31.9 million as of June 30, 2016 on direct costs for the Phase 3 clinical trial.

XML 22 R12.htm IDEA: XBRL DOCUMENT

G. COMMITMENTS AND CONTINGENCIES

9 Months Ended

Jun. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

G. COMMITMENTS AND CONTINGENCIES

Clinical Research Agreements

The arbitration hearing on the merits (the “trial”) has been scheduled to commence on September 7, 2016.

Lease Agreements

XML 23 R13.htm IDEA: XBRL DOCUMENT

H. PATENTS

9 Months Ended

Jun. 30, 2016

Accounting Policies [Abstract]

H. PATENTS

Three months ending September 30, 2016	$	9,210
Year ending September 30,
2017		36,841
2018		36,507
2019		34,804
2020		31,611
2021		28,311
Thereafter		89,209
Total	$	266,493

XML 24 R14.htm IDEA: XBRL DOCUMENT

I. LOSS PER COMMON SHARE

9 Months Ended

Jun. 30, 2016

Accounting Policies [Abstract]

I. LOSS PER COMMON SHARE

The following tables provide the details of the basic and diluted loss per-share (LPS) computations:

	Nine Months Ended June 30, 2016
	Net Loss			Weighted Average Shares		LPS


Basic and dilutive LPS	$	(10,352,366	)		117,412,443	$	(0.09	)

	Three Months Ended June 30, 2016
	Net Loss			Weighted Average Shares		LPS

Basic and dilutive LPS	$	(3,849,324	)		124,132,500	$	(0.03	)

	Nine Months Ended June 30, 2015
	Net Loss			Weighted Average Shares		LPS

Basic and dilutive LPS	$	(24,830,691	)		77,625,511	$	(0.32	)

	Three Months Ended June 30, 2015
	Net Loss			Weighted Average Shares		LPS

Basic LPS	$	(4,429,137	)		83,796,311	$	(0.05	)
Gain on derivatives		(1,100,760	)		1,337,796

Dilutive LPS	$	(5,529,897	)		85,134,107	$	(0.06	)

In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, Earnings Per Share, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of June 30:

	2016		2015

Options and Warrants		86,066,292		38,786,333
Convertible Debt		-		1,871,283
Unvested Restricted Stock		15,100,000		15,100,000
Total		101,166,292		55,757,616

XML 25 R15.htm IDEA: XBRL DOCUMENT

J. SUBSEQUENT EVENTS

9 Months Ended

Jun. 30, 2016

Subsequent Events [Abstract]

J. SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.

XML 26 R16.htm IDEA: XBRL DOCUMENT

A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)	9 Months Ended
	Jun. 30, 2016
A. Summary Of Significant Accounting Policies Policies
Basis of Presentation	The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s annual report on Form 10-K for the year ended September 30, 2015. In the opinion of management, the accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the Company’s financial position as of June 30, 2016 and the results of its operations for the nine and three months then ended. The condensed balance sheet as of September 30, 2015 is derived from the September 30, 2015 audited financial statements. Significant accounting policies have been consistently applied in the interim financial statements and the annual financial statements. The results of operations for the nine and three months ended June 30, 2016 are not necessarily indicative of the results to be expected for the entire year.
Research and Office Equipment and Leasehold Improvements	Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Research and office equipment are reviewed on a quarterly basis to determine if any of the assets are impaired.
Patents	Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made in the period identified. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.
Research and Development Costs	Research and development costs are expensed as incurred.
Income Taxes	The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2016 and September 30, 2015.
Derivative Instruments	The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are remeasured at fair value at the end of each reporting period as long as they are outstanding.
Deferred Rent (Asset)	Consideration paid, including deposits, related to operating leases is recorded as a deferred rent asset and amortized as rent expense over the lease term. Interest on deferred rent is calculated at 3% on the funds deposited on the manufacturing facility and is included in deferred rent. This interest income will be used to offset future rent.
Stock-Based Compensation	Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation – Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period. Equity instruments issued to non-employees are accounted for in accordance with ASC 505-50, “Equity-Based Payments to Non Employees.” Accordingly, compensation is recognized when goods or services are received and options issued are measured using the Black-Scholes valuation model. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected life of the options. The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders. The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s common stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with term equal to the expected life of the option. Historical data was used to estimate option exercise and employee termination within the valuation model. The expected term of options represents the period of time that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period. Vesting of restricted stock granted under the Incentive Stock Bonus Plan is subject to service, performance and market conditions and meets the classification of equity awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.
Reclassification	Certain prior year items have been reclassified to conform to the current year presentation. Such reclassifications include approximately $145,000 between related party notes payable and additional paid-in capital to reflect the modification of the note payable to the de Clara Trust in July 2015, which was accounted for as an extinguishment.

XML 27 R17.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Tables)

9 Months Ended

Jun. 30, 2016

C. Stockholders Equity Tables

Stock options, stock bonuses and compensation granted by the Company

Stock options, stock bonuses and compensation granted by the Company as of June 30, 2016 are as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans

Incentive Stock Options Plans		1,960,000		1,685,966		N/A		11,334
Non-Qualified Stock Option Plans		7,680,000		6,005,721		N/A		1,062,861
Stock Bonus Plans		3,594,000		N/A		2,562,950		1,030,223
Stock Compensation Plan		3,350,000		N/A		1,767,047		1,549,905
Incentive Stock Bonus Plan		16,000,000		N/A		15,600,000		400,000

Stock options, stock bonuses and compensation granted by the Company as of September 30, 2015 are as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans

Incentive Stock Option Plans		1,960,000		1,690,665		N/A		6,635
Non-Qualified Stock Option Plans		7,680,000		5,849,103		N/A		1,219,479
Bonus Plans		3,594,000		N/A		1,643,714		1,949,459
Stock Compensation Plan		3,350,000		N/A		1,423,999		1,892,950
Incentive Stock Bonus Plan		16,000,000		N/A		15,600,000		400,000

Stock option activity:

	Nine Months Ended June 30,
	2016		2015
Granted		210,000		803,700
Forfeited		55,998		137,249

	Three Months Ended June 30,
	2016		2015
Granted		0		801,700
Forfeited		5,000		27,833

Schedule of employees and non-employees stock compensation

Stock-Based Compensation Expense

	Nine Months Ended June 30,
	2016		2015
Employees	$	1,263,662	$	4,570,999
Non-employees	$	618,890	$	437,729

	Three months Ended June 30,
	2016		2015
Employees	$	418,562	$	619,145
Non-employees	$	146,830	$	137,600

Derivative Liabilities, Warrants and Other Options

Warrant	Issue Date	Shares Issuable upon Exercise of Warrant		Exercise Price		Expiration Date	Refer-ence

Series R	12/6/12		2,625,000	$	4.00	12/6/16		1
Series S	10/11/13 -10/24/14		25,928,010	$	1.25	10/11/18		1
Series U	4/17/14		445,514	$	1.75	10/17/17		1
Series V	5/28/15		20,253,164	$	0.79	5/28/20		1
Series W	10/28/15		17,223,248	$	0.67	10/28/20		1
Series Z	5/23/16		6,600,000	$	0.55	11/23/21		1
Series ZZ	5/23/16		500,000	$	0.55	5/18/21		1
Series X	1/13/16		3,000,000	$	0.37	1/13/21		2
Series Y	2/15/16		650,000	$	0.48	2/15/21		2
Series N	8/18/08		2,844,627	$	0.53	8/18/17
Series P	2/10/12		590,001	$	4.50	3/6/17
Consultants	12/2/11- 1/1/16		440,000	$	0.37- $3.50	10/27/16- 12/31/18		3

The following chart presents the derivative liabilities, warrants and other options outstanding at September 30, 2015:

Warrant	Issue Date	Shares Issuable upon Exercise of Warrants		Exercise Price		Expiration Date	Refer-ence

Series N	8/18/08		2,844,627		0.53	8/18/17
Series Q	6/21/12		1,200,000		5.00	12/22/15		1
Series R	12/6/12		2,625,000		4.00	12/6/16		1
Series S	10/11/13- 10/24/14		25,928,010		1.25	10/11/18		1
Series U	4/17/14		445,514		1.75	10/17/17		1
Series V	5/28/15		20,253,164		0.79	5/28/20		1
Series P	2/10/12		590,001		4.50	3/6/17
Consultants	10/14/05 – 7/1/15		238,000		0.66 – 20.00	10/14/15 - 6/30/18		3

Tabular disclosure of derivative liabilities at fair value

The table below presents the derivative instruments and their respective balances at the balance sheet dates:

	June 30, 2016		September 30, 2015
Series S warrants	$	3,930,686	$	7,363,555
Series U warrants		4,455		44,551
Series V warrants		3,443,038		6,278,481
Series W warrants		3,557,971		-
Series Z warrants		1,756,982		-
Series ZZ warrants		129,920		-

Total derivative liabilities	$	12,823,052	$	13,686,587

Schedule Of Gains and (Losses) on Derivative Liabilities

The gains on the derivative instruments are as follows:

	Nine Months Ended June 30,
	2016		2015
Series A through E warrants	$	-	$	6,105
Series H warrants		-		12,000
Series Q warrants		-		12,000
Series R warrants		-		131,250
Series S warrants		3,432,869		472,487
Series U warrants		40,096		74,352
Series V warrants		2,835,443		1,100,760
Series W warrants		1,502,800		-
Series Z warrants		210,848		-
Series ZZ warrants		15,918		-

Gain on derivative instruments	$	8,037,974	$	1,808,954

	Three Months Ended June 30,
	2016		2015
Series H warrants	$	-	$	12,000
Series Q warrants		-		12,000
Series R warrants		-		105,000
Series S warrants		285,208		3,111,361
Series U warrants		13,366		87,659
Series V warrants		1,012,658		1,100,760
Series W warrants		970,746
Series Z warrants		210,848		-
Series ZZ warrants		15,918		-

Gain on derivative instruments	$	2,508,744	$	4,428,780

XML 28 R18.htm IDEA: XBRL DOCUMENT

D. FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Jun. 30, 2016

D. Fair Value Measurements Tables

Measured at fair value on a recurring basis

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total

Derivative instruments	$	3,930,686	$	-	$	8,892,366	$	12,823,052

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2015:

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total

Derivative instruments	$	7,363,555	$	-	$	6,323,032	$	13,686,587

Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)

	(9 months ended)			(12 months ended)
	June 30, 2016			September 30, 2015
Beginning balance	$	6,323,032		$	307,894
Issuances		7,174,439			8,003,220
Realized and unrealized gains		(4,605,105	)		(1,988,082	)
Ending balance	$	8,892,366		$	6,323,032

XML 29 R19.htm IDEA: XBRL DOCUMENT

H. PATENTS (Tables)

9 Months Ended

Jun. 30, 2016

H. Patents Tables

Schedule of total estimated future amortization

Three months ending September 30, 2016	$	9,210
Year ending September 30,
2017		36,841
2018		36,507
2019		34,804
2020		31,611
2021		28,311
Thereafter		89,209
Total	$	266,493

XML 30 R20.htm IDEA: XBRL DOCUMENT

I. LOSS PER COMMON SHARE (Tables)

9 Months Ended

Jun. 30, 2016

I. Loss Per Common Share Tables

Computation of dilutive net loss per share

The following tables provide the details of the basic and diluted loss per-share (LPS) computations:

	Nine Months Ended June 30, 2016
	Net Loss			Weighted Average Shares		LPS


Basic and dilutive LPS	$	(10,352,366	)		117,412,443	$	(0.09	)

	Three Months Ended June 30, 2016
	Net Loss			Weighted Average Shares		LPS

Basic and dilutive LPS	$	(3,849,324	)		124,132,500	$	(0.03	)

	Nine Months Ended June 30, 2015
	Net Loss			Weighted Average Shares		LPS

Basic and dilutive LPS	$	(24,830,691	)		77,625,511	$	(0.32	)

	Three Months Ended June 30, 2015
	Net Loss			Weighted Average Shares		LPS

Basic LPS	$	(4,429,137	)		83,796,311	$	(0.05	)
Gain on derivatives		(1,100,760	)		1,337,796

Dilutive LPS	$	(5,529,897	)		85,134,107	$	(0.06	)

Antidilutive securities

	2016		2015

Options and Warrants		86,066,292		38,786,333
Convertible Debt		-		1,871,283
Unvested Restricted Stock		15,100,000		15,100,000
Total		101,166,292		55,757,616

XML 31 R21.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Details) - shares	Jun. 30, 2016	Sep. 30, 2015
Incentive Stock Option Plans
Total Shares Reserved Under Plans	1,960,000	1,960,000
Shares Reserved for Outstanding Options	1,685,966	1,690,665
Remaining Options/Shares Under Plans	11,334	6,635
NonQualifiedStockOptionPlansMember
Total Shares Reserved Under Plans	7,680,000	7,680,000
Shares Reserved for Outstanding Options	6,005,721	5,849,103
Remaining Options/Shares Under Plans	1,062,861	1,219,479
Stock Bonus Plans
Total Shares Reserved Under Plans	3,594,000	3,594,000
Shares Issued	2,562,950	1,643,714
Remaining Options/Shares Under Plans	1,030,223	1,949,459
Stock Compensation Plan
Total Shares Reserved Under Plans	3,350,000	3,350,000
Shares Issued	1,767,047	1,423,999
Remaining Options/Shares Under Plans	1,549,905	1,892,950
Incentive Stock Bonus Plan
Total Shares Reserved Under Plans	16,000,000	16,000,000
Shares Issued	15,600,000	15,600,000
Remaining Options/Shares Under Plans	400,000	400,000

XML 32 R22.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Details 1) - shares	3 Months Ended		9 Months Ended
C. STOCKHOLDERS EQUITY (Details 1) - shares	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
C. Stockholders Equity Details 1
Granted	0	801,700	210,000	803,700
Forfeited	5,000	27,833	55,998	137,249

XML 33 R23.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Details 2) - USD ($)	3 Months Ended		9 Months Ended
C. STOCKHOLDERS EQUITY (Details 2) - USD ($)	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
C. Stockholders Equity Details 2
Employees	$ 418,562	$ 619,145	$ 1,263,662	$ 4,570,999
Non-employees	$ 146,830	$ 137,600	$ 618,890	$ 437,729

XML 34 R24.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Details 3) - $ / shares	9 Months Ended	12 Months Ended
C. STOCKHOLDERS EQUITY (Details 3) - $ / shares	Jun. 30, 2016	Sep. 30, 2015
Series R [Member]
STOCKHOLDERS' EQUITY
Issue Date	12/6/2012	12/6/2012
Shares Issuable upon Exercise of Warrant	2,625,000	2,625,000
Exercise Price	$ 4	$ 4
Expiration Date	12/6/2016	12/6/2016
Series S [Member]
STOCKHOLDERS' EQUITY
Issue Date	10/11/13 -10/24/14	10/11/13- 10/24/14
Shares Issuable upon Exercise of Warrant	25,928,010	25,928,010
Exercise Price	$ 1.25	$ 1.25
Expiration Date	10/11/2018	10/11/2018
Series U [Member]
STOCKHOLDERS' EQUITY
Issue Date	4/17/2014	4/17/2014
Shares Issuable upon Exercise of Warrant	445,514	445,514
Exercise Price	$ 1.75	$ 1.75
Expiration Date	10/17/2017	10/17/2017
Series V [Member]
STOCKHOLDERS' EQUITY
Issue Date	5/28/2015	5/28/2015
Shares Issuable upon Exercise of Warrant	20,253,164	20,253,164
Exercise Price	$ 0.79	$ 0.79
Expiration Date	5/28/2020	5/28/2020
Series W [Member]
STOCKHOLDERS' EQUITY
Issue Date	10/28/2015
Shares Issuable upon Exercise of Warrant	17,223,248
Exercise Price	$ 0.67
Expiration Date	10/28/20
Series X [Member]
STOCKHOLDERS' EQUITY
Issue Date	1/13/2016
Shares Issuable upon Exercise of Warrant	3,000,000
Exercise Price	$ 0.37
Expiration Date	1/13/2021
Series Y [Member]
STOCKHOLDERS' EQUITY
Issue Date	2/15/2016
Shares Issuable upon Exercise of Warrant	650,000
Exercise Price	$ 0.48
Expiration Date	2/15/2021
Series N [Member]
STOCKHOLDERS' EQUITY
Issue Date	8/18/2008	8/18/2008
Shares Issuable upon Exercise of Warrant	2,844,627	2,844,627
Exercise Price	$ 0.53	$ 0.53
Expiration Date	8/18/2017	8/18/2017
Series P [Member]
STOCKHOLDERS' EQUITY
Issue Date	2/10/2012	2/10/2012
Shares Issuable upon Exercise of Warrant	590,001	590,001
Exercise Price	$ 4.5	$ 4.5
Expiration Date	3/6/2017	3/6/2017
Consultants [Member]
STOCKHOLDERS' EQUITY
Issue Date	12/2/11- 10/1/16	10/14/05 – 7/1/15
Shares Issuable upon Exercise of Warrant	440,000	238,000
Exercise Price Minimum	$ 0.37	$ 0.66
Exercise Price Maximum	$ 3.50	$ 20.00
Expiration Date	10/27/16- 12/31/18	10/14/15 - 6/30/18
Series Q [Member]
STOCKHOLDERS' EQUITY
Issue Date		6/21/2012
Shares Issuable upon Exercise of Warrant		1,200,000
Exercise Price		$ 5
Expiration Date		12/22/2015

XML 35 R25.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Details 4) - USD ($)	3 Months Ended		9 Months Ended
C. STOCKHOLDERS EQUITY (Details 4) - USD ($)	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2015
C. Stockholders Equity Details 4
Series S warrants	$ 3,930,686		$ 3,930,686		$ 7,363,555
Series U warrants	4,455		4,455		44,551
Series V warrants	3,443,038		3,443,038		6,278,481
Series W warrants	3,557,971		3,557,971		0
Series Z warrants	1,756,982		1,756,982		0
Series ZZ warrants	129,920		129,920		0
Total derivative liabilities	12,823,052		12,823,052		$ 13,686,587
Series A through E warrants			0	$ 6,105
Series H warrants	0	$ 12,000	0	12,000
Series Q warrants	0	12,000	0	12,000
Series R warrants	0	105,000	0	131,250
Series S warrants	285,208	3,111,361	3,432,869	472,487
Series U warrants	13,366	87,659	40,096	74,352
Series V warrants	1,012,658	1,100,760	2,835,443	1,100,760
Series W warrants	970,746	0	1,502,800	0
Series Z warrants	210,848	0	210,848	0
Series ZZ warrants	15,918	0	15,918	0
Gain on derivative instruments	$ 2,508,744	$ 4,428,780	$ 8,037,974	$ 1,808,954

XML 36 R26.htm IDEA: XBRL DOCUMENT

D. FAIR VALUE MEASUREMENTS (Details) - USD ($)	Jun. 30, 2016	Sep. 30, 2015
Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)
Derivative instruments	$ 3,930,686	$ 7,363,555
Significant Other Observable Inputs (Level 2)
Derivative instruments	0	0
Significant Unobservable Inputs (Level 3)
Derivative instruments	8,892,366	6,323,032
Total
Derivative instruments	$ 12,823,052	$ 13,686,587

XML 37 R27.htm IDEA: XBRL DOCUMENT

D. FAIR VALUE MEASUREMENTS (Details 1) - USD ($)	9 Months Ended	12 Months Ended
D. FAIR VALUE MEASUREMENTS (Details 1) - USD ($)	Jun. 30, 2016	Sep. 30, 2015
D. Fair Value Measurements Details 1
Beginning balance	$ 6,323,032	$ 307,894
Issuances	7,174,439	8,003,220
Realized and unrealized (gains) losses	(4,605,105)	(1,988,082)
Ending balance	$ 8,892,336	$ 6,323,032

XML 38 R28.htm IDEA: XBRL DOCUMENT

E. RELATED PARTY LOAN (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
E. RELATED PARTY LOAN (Details Narrative) - USD ($)	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
E. Related Party Loan Details Narrative
Interest expense paid to Mr. de Clara	$ 0	$ 41,000	$ 43,000	$ 124,000

XML 39 R29.htm IDEA: XBRL DOCUMENT

H. PATENTS (Details) - USD ($)	Jun. 30, 2016	Sep. 30, 2015
H. Patents Details
Six months ending September 30, 2016	$ 9,210
Year ending September 30, 2017	36,841
Year ending September 30, 2018	36,507
Year ending September 30, 2019	34,804
Year ending September 30, 2020	31,611
Year ending September 30, 2021	28,311
Thereafter	89,209
Total	$ 266,493	$ 291,564

XML 40 R30.htm IDEA: XBRL DOCUMENT

H. PATENTS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
H. PATENTS (Details Narrative) - USD ($)	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
H. Patents Details Narrative
Patent impairment charges	$ 0	$ 0	$ 0	$ 0
Amortization of patent costs	$ 12,000	$ 12,000	$ 30,000	$ 31,000

XML 41 R31.htm IDEA: XBRL DOCUMENT

I. LOSS PER COMMON SHARE (Details) - USD ($)	3 Months Ended		9 Months Ended
I. LOSS PER COMMON SHARE (Details) - USD ($)	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
I. Loss Per Common Share Details
Net Loss	$ (3,849,324)	$ (4,429,137)	$ (10,352,366)	$ (24,830,691)
Gain on derivatives		(1,100,760)
Net Loss, Diluted		$ (5,529,897)
Weighted Average Shares - Basic	124,132,500	83,796,311
Gain on derivatives, shares		1,337,796
Weighted Average Shares - Diluted	124,132,500	85,134,107
Weighted Average Shares - Basic and Diluted			117,412,443	77,625,511
LPS - Basic and Diluted			$ (0.09)	$ (0.32)
LPS - Basic	$ (0.03)	$ (0.05)
LPS - Diluted	$ (0.03)	$ (0.06)

XML 42 R32.htm IDEA: XBRL DOCUMENT

I. LOSS PER COMMON SHARE (Details 1) - shares	9 Months Ended
I. LOSS PER COMMON SHARE (Details 1) - shares	Jun. 30, 2016	Jun. 30, 2015
I. Loss Per Common Share Details 1
Options and Warrants	86,066,292	38,786,333
Convertible Debt	0	1,871,283
Unvested Restricted Stock	15,100,000	15,100,000
Total	101,166,292	55,757,616

EXCEL 43 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 64 190 1 false 20 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://cel-sci.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - BALANCE SHEETS Sheet http://cel-sci.com/role/BalanceSheets BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - BALANCE SHEETS (Parenthetical) Sheet http://cel-sci.com/role/BalanceSheetsParenthetical BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - STATEMENTS OF OPERATIONS Sheet http://cel-sci.com/role/StatementsOfOperations STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000006 - Statement - STATEMENTS OF CASH FLOWS Sheet http://cel-sci.com/role/StatementsOfCashFlows STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 00000007 - Disclosure - A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://cel-sci.com/role/A.SummaryOfSignificantAccountingPolicies A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 6 false false R7.htm 00000008 - Disclosure - B. NEW ACCOUNTING PRONOUNCEMENTS Sheet http://cel-sci.com/role/B.NewAccountingPronouncements B. NEW ACCOUNTING PRONOUNCEMENTS Notes 7 false false R8.htm 00000009 - Disclosure - C. STOCKHOLDERS EQUITY Sheet http://cel-sci.com/role/C.StockholdersEquity C. STOCKHOLDERS EQUITY Notes 8 false false R9.htm 00000010 - Disclosure - D. FAIR VALUE MEASUREMENTS Sheet http://cel-sci.com/role/D.FairValueMeasurements D. FAIR VALUE MEASUREMENTS Notes 9 false false R10.htm 00000011 - Disclosure - E. RELATED PARTY LOAN Sheet http://cel-sci.com/role/E.RelatedPartyLoan E. RELATED PARTY LOAN Notes 10 false false R11.htm 00000012 - Disclosure - F. OPERATIONS AND FINANCING Sheet http://cel-sci.com/role/F.OperationsAndFinancing F. OPERATIONS AND FINANCING Notes 11 false false R12.htm 00000013 - Disclosure - G. COMMITMENTS AND CONTINGENCIES Sheet http://cel-sci.com/role/G.CommitmentsAndContingencies G. COMMITMENTS AND CONTINGENCIES Notes 12 false false R13.htm 00000014 - Disclosure - H. PATENTS Sheet http://cel-sci.com/role/H.Patents H. PATENTS Notes 13 false false R14.htm 00000015 - Disclosure - I. LOSS PER COMMON SHARE Sheet http://cel-sci.com/role/I.LossPerCommonShare I. LOSS PER COMMON SHARE Notes 14 false false R15.htm 00000016 - Disclosure - J. SUBSEQUENT EVENTS Sheet http://cel-sci.com/role/J.SubsequentEvents J. SUBSEQUENT EVENTS Notes 15 false false R16.htm 00000017 - Disclosure - A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES) Sheet http://cel-sci.com/role/A.SummaryOfSignificantAccountingPoliciesPolicies A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES) Notes 16 false false R17.htm 00000018 - Disclosure - C. STOCKHOLDERS EQUITY (Tables) Sheet http://cel-sci.com/role/C.StockholdersEquityTables C. STOCKHOLDERS EQUITY (Tables) Tables http://cel-sci.com/role/C.StockholdersEquity 17 false false R18.htm 00000019 - Disclosure - D. FAIR VALUE MEASUREMENTS (Tables) Sheet http://cel-sci.com/role/D.FairValueMeasurementsTables D. FAIR VALUE MEASUREMENTS (Tables) Tables http://cel-sci.com/role/D.FairValueMeasurements 18 false false R19.htm 00000020 - Disclosure - H. PATENTS (Tables) Sheet http://cel-sci.com/role/H.PatentsTables H. PATENTS (Tables) Tables http://cel-sci.com/role/H.Patents 19 false false R20.htm 00000021 - Disclosure - I. LOSS PER COMMON SHARE (Tables) Sheet http://cel-sci.com/role/I.LossPerCommonShareTables I. LOSS PER COMMON SHARE (Tables) Tables http://cel-sci.com/role/I.LossPerCommonShare 20 false false R21.htm 00000022 - Disclosure - C. STOCKHOLDERS EQUITY (Details) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails C. STOCKHOLDERS EQUITY (Details) Details http://cel-sci.com/role/C.StockholdersEquityTables 21 false false R22.htm 00000023 - Disclosure - C. STOCKHOLDERS EQUITY (Details 1) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails1 C. STOCKHOLDERS EQUITY (Details 1) Details http://cel-sci.com/role/C.StockholdersEquityTables 22 false false R23.htm 00000024 - Disclosure - C. STOCKHOLDERS EQUITY (Details 2) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails2 C. STOCKHOLDERS EQUITY (Details 2) Details http://cel-sci.com/role/C.StockholdersEquityTables 23 false false R24.htm 00000025 - Disclosure - C. STOCKHOLDERS EQUITY (Details 3) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails3 C. STOCKHOLDERS EQUITY (Details 3) Details http://cel-sci.com/role/C.StockholdersEquityTables 24 false false R25.htm 00000026 - Disclosure - C. STOCKHOLDERS EQUITY (Details 4) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails4 C. STOCKHOLDERS EQUITY (Details 4) Details http://cel-sci.com/role/C.StockholdersEquityTables 25 false false R26.htm 00000027 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details) Sheet http://cel-sci.com/role/D.FairValueMeasurementsDetails D. FAIR VALUE MEASUREMENTS (Details) Details http://cel-sci.com/role/D.FairValueMeasurementsTables 26 false false R27.htm 00000028 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details 1) Sheet http://cel-sci.com/role/D.FairValueMeasurementsDetails1 D. FAIR VALUE MEASUREMENTS (Details 1) Details http://cel-sci.com/role/D.FairValueMeasurementsTables 27 false false R28.htm 00000029 - Disclosure - E. RELATED PARTY LOAN (Details Narrative) Sheet http://cel-sci.com/role/E.RelatedPartyLoanDetailsNarrative E. RELATED PARTY LOAN (Details Narrative) Details http://cel-sci.com/role/E.RelatedPartyLoan 28 false false R29.htm 00000030 - Disclosure - H. PATENTS (Details) Sheet http://cel-sci.com/role/H.PatentsDetails H. PATENTS (Details) Details http://cel-sci.com/role/H.PatentsTables 29 false false R30.htm 00000031 - Disclosure - H. PATENTS (Details Narrative) Sheet http://cel-sci.com/role/H.PatentsDetailsNarrative H. PATENTS (Details Narrative) Details http://cel-sci.com/role/H.PatentsTables 30 false false R31.htm 00000032 - Disclosure - I. LOSS PER COMMON SHARE (Details) Sheet http://cel-sci.com/role/I.LossPerCommonShareDetails I. LOSS PER COMMON SHARE (Details) Details http://cel-sci.com/role/I.LossPerCommonShareTables 31 false false R32.htm 00000033 - Disclosure - I. LOSS PER COMMON SHARE (Details 1) Sheet http://cel-sci.com/role/I.LossPerCommonShareDetails1 I. LOSS PER COMMON SHARE (Details 1) Details http://cel-sci.com/role/I.LossPerCommonShareTables 32 false false All Reports Book All Reports cvm-20160630.xml cvm-20160630.xsd cvm-20160630_cal.xml cvm-20160630_def.xml cvm-20160630_lab.xml cvm-20160630_pre.xml true true ZIP 49 0001654954-16-001315-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-16-001315-xbrl.zip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